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Abstract 
Purpose:  The purpose of this work was to investigate the use of pre-calculated Monte Carlo 
(MC) ovoid and source-based attenuation-correction factors that would correct a commercially-
available brachytherapy treatment planning system (TPS) generated plan in order to account for 
any dosimetric effects due to the presence of intracavitary brachytherapy (ICBT) applicators 
during treatment delivery.   
Methods:  A MC model of an ICBT CT-MR compatible ovoid applicator set was confirmed 
utilizing radiochromic film (RCF).  MC was used to simulate dose distributions resulting from 
eight source-dwell-positions within the ICBT applicator.  Also, the American Association of 
Physicist in Medicine Task Group 43 Report (AAPM TG-43) was utilized to calculate absolute 
dose rate around a microSelectron version 2 
192
Ir source contained in water.  With these dose 
distributions, a library of ovoid and source-based 3D attenuation-correction factor datasets 
characterizing the dosimetric effects of the ICBT applicator was developed.  Appropriate 
attenuation-correction factors were then applied to correct a brachytherapy TPS-calculated plan.  
Several plans with different maximum dwell-time gradients (∇dt) were compared to evaluate the 
effectiveness of both correction methods with respect to criteria of acceptability being within +/- 
2% absolute dose or +/- 2 mm distance-to-agreement (DTA).   
Results: RCF confirmation measurements from 3 active dwell-positions in a single ovoid agreed 
with MC simulated planes with over 96% of points agreeing within 2% or 2 mm DTA.  Plans 
generated by Oncentra TPS can be corrected utilizing either the ovoid-based or source-based 
correction methods to agree with full simulated Monte Carlo datasets to within +/- 2% or +/- 
2mm DTA.  Although, dwell-time combinations utilized in this study with a maximum dwell-
time gradient above 10% is a threshold for the ovoid- based correction scheme to correct the TG-
x 
 
43 calculation.  The source- based correction method consistently results in 100% agreement 
between a corrected plan and the equivalent MC generated plan.   
Conclusions:  The MC model is sufficient to predict measured RCF dose distributions 
accurately.  Source- based correction factors can be applied to correct a TG-43 based treatment 
plan to match a full MC simulation. 
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Chapter 1 Introduction 
1.1 Brachytherapy for the Treatment of Cervical Carcinoma 
Intracavitary brachytherapy (ICBT) has an advantage over external beam radiotherapy 
(EBRT) for local control because it allows for dose escalation while sparing normal tissue 
surrounding the treatment volume.  Cervical cancer treatment is typically a combination of 
EBRT and ICBT.  EBRT is generally delivered first in order to reduce the volume of the primary 
disease before ICBT as well as to control the spread of disease at the periphery of the tumor bed.  
Unlike in EBRT, where radiation is directed at the disease from outside the body, ICBT involves 
placing a radioactive source within close proximity or inside the target tissue.  Due to the inverse 
square law, i.e. the exposure due to a source is inversely proportional to the square of the 
distance from the source; the high-dose region delivered from a radioactive source is localized 
and has a very steep dose gradient.   
The current ICBT cervical technique is to remotely afterload radioactive sources into a 
tandem and ovoids once they have been placed in the uterine canal.  A photo of Nucletron’s 
computed tomography, magnetic resonance (CT-MR) compatible tandem and ovoids is shown in 
Figure 1.1.  During an ICBT treatment, the radioactive source is remotely after loaded into the 
applicator and the source steps to varying positions (i.e., 5 mm back) within the applicator shaft.  
The process of moving a single source to multiple positions in the applicator simulates a single-
long source in the applicator.  The design of an applicator allows delivery of the radioactive 
source and a specific dose distribution around the disease.   
A tandem is a hollow tube and is inserted directly through the cervical opening into the 
endometrial cavity (inner uterine lining).  Although only 5 cm of the tandem is placed in the 
uterus, tandems are approximately 25 cm in length and are available in varying curvatures (i.e. 
15º, 30º, 45º) to accommodate variations in disease location and patient anatomies.  The ovoids 
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are positioned lateral to the cervical opening on opposite sides within the vaginal fornices.  In 
addition to the ICBT technique, a “packing” procedure holds the ovoids relatively stationary 
post-insertion and displaces the rectum and bladder away from the high dose volume.  “Packing” 
refers to inserting gauze around the ovoids in the patient’s anterior and posterior directions.  This 
additional procedure takes advantage of the distortable characteristic of the vagina and the 
inverse-square dose falloff applicable with ICBT.   
 
Figure 1.1:  CT-MR Fletcher applicator set.   
 1.2 Prescription Methodologies for Gynecological ICBT  
 Dosimetry systems for brachytherapy consist of a set of rules which, when followed, 
would deliver dose in a clinically desirable distribution to a designated anatomical region.  These 
guidelines specify treatment delivery parameters in terms of dose, time, and source position in an 
attempt to deliver a prescribed dose in a reproducible manner.  Dosimetry systems also provide 
standardization for treatments which allow inter-institutional comparison of results.   
1.2.1 Manchester System 
The Manchester system, developed by Ralston Paterson, M.D. and Herbert Parker, Ph.D. 
at Manchester Hospital, defines four points at which delivered dose rates are to be considered: 
point A, point B, a bladder point, and a rectum point.  The duration of the implant is based on the 
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dose rate calculated at point A, although the dose at the other points are recorded and evaluated 
during the treatment planning process.  As illustrated in Figure 1.2, the left and right point A’s 
were defined as 2 cm superior and lateral to the vaginal fornices.  Point B was defined 3 cm 
lateral to the left and right point A’s.  Ideally, Point A represents an anatomical location where 
the uterine vessels cross the ureter, and point B represents the location of lymph nodes.  Within 
the Manchester system, the locations of prescription points are a function of source orientations 
and not specified directly in terms of a patient’s anatomical structures.  For an ICBT cervical 
treatment, the delivered dose distribution ideally resembles a “pear shape” when viewed in the 
anterior-posterior (AP) plane.  In some patient instances, this method of defining prescribed 
doses to a specific point risks under dosage of a large cervical tumor or over dosage of small 
tumors [1].   
 
Figure 1.2:  Anatomy illustration to show relationship of points A and B to the 
vaginal fornices and uterus as described using the Manchester system.   
1.2.2 International Commission on Radiation Units (ICRU) Report 38 Guidelines for ICBT 
of Cervical Disease 
The International Commission on Radiation Units (ICRU) Report 38 introduced a 
dosimetry system, incorporating recommendations of the European Group of Brachytherapy, 
which recommends specifying prescription dose to a target volume, rather than to a discrete 
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point [2].  The method addresses the inherent ambiguity of dose delivered to a target volume 
when merely prescribing dose to a set of points.  For an ICBT cervical treatment, the report 
recommends dose to be prescribed as an isodose surface that surrounds the target volume (uterus, 
cervix).  Recommendations are given to use certain points for reporting dose to organs at risk 
(OAR) such as the bladder point, rectal point, lymphatic trapezoid of Fletcher points, and pelvic 
wall points.  However, it has been shown that the ICRU reference points for the bladder and the 
rectum do not necessarily indicate the maximum dose delivered to these OARs [3].  3D treatment 
planning analysis has shown maximum bladder doses and maximum rectal doses can be as much 
as 2.3 and 1.3 times higher, respectively, when determined using computed tomography (CT) 
relative to the ICRU reference points [4].   
1.2.3 American Brachytherapy Society Guidelines for ICBT of Gynecological Disease 
 The American Brachytherapy Society  recommends prescribing dose for cervical ICBT to 
a new point, other than point A, where it is farther from the high-dose gradient fall off from the 
ovoids [5].  This point, designated point H, relocates the prescription point away from the high-
dose high-gradient fall off region that the ICRU/Manchester point A lies within, to an area of 
high-dose, low dose-gradient fall off.  It was suggested as a minor change in the location of point 
A because it results in a significant difference in dose which may lead to inconsistencies in 
patient treatments.  This new point (Point H) is located 2 cm superiorly to the cervical os plus the 
radius of the ovoids, and then 2-cm in the lateral direction.   
1.3 Dose Calculation Methods for Brachytherapy 
Accurate dose calculation of an ICBT cervical treatment is an important and challenging 
task.  In general, radiation dose calculations involve the determination of the amount of energy 
deposited within a volume or point of interest.  Manual dose calculations utilize published tables 
which characterize a dose distribution for a specified isotope and encapsulation in a 
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homogeneous material where the reference dose rate is estimated and the treatment time is 
calculated.  Although manual tables are convenient for two dimensional (2D) dose calculations, 
treatment planning system (TPS) computers are able to quickly calculate dose to a three 
dimensional (3D) volume. Also, because the human body is not homogeneous, it would be 
advantageous for a calculation method to take into account tissue heterogeneities.   
1.3.1 Analytical Method:  American Association of Physicist in Medicine Task Group-43 
(AAPM TG-43) Methodology 
 Most commercially available brachytherapy TPS utilize the dose calculation methods 
presented within the American Association of Medical Physics Task Group-43 (AAPM TG-43) 
report published in 1995 which characterizes the dose distribution in water as a function of 
isotope and source construction.  This report presented a formalism that clearly defines the 
necessary physical quantities for point dosimetry [6].  The formalism has one dimensional and 
2D formats: the point-source approximation and the line-source approximation.  For dose 
distributions resulting from multiple sources or single source plans with multiple dwell-positions, 
this methodology relies on superposition of single-source dose distributions.  This method 
assumes a 3D cylindrically symmetrical dose distribution as the calculation utilizes a 2D dataset 
for commissioning. 
The AAPM TG-43 2D dose rate calculation equation is: 
    (1.1) 
 
where r denotes the distance from the center of the radioactive source to the point of interest, and 
θ denotes the polar angle specifying the point-of-interest relative to the source longitudinal axis. 
As illustrated in Figure 1.3, the reference angle, θ0, and reference distance, r0, define a point on 
the source transverse plane, and are specified to be 90° and 1 cm, respectively. 
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Figure 1.3:  Definition of the coordinate system utilized within the AAPM TG-43 
formalism. 
Air-kerma strength, SK, is the air-kerma rate, Kδ (d), in vacuo, due to photons with 
energies greater than δ, at distance d from the source, multiplied by the square of this distance.  
Air kerma rate measurements should be made in air and corrected for photon attenuation and 
scattering in air between the source and detector.  In lieu of measurements, Price et al. has shown 
that a Monte Carlo (MC) simulation can be used to calculate air kerma rate [7].  The distance d 
can be any distance that is large relative to the maximum linear dimension of the radioactivity 
distribution so that SK is independent of distance [1].  The units of air-kerma strength, denoted as 
U, are μGy h-1 m2. 
The dose-rate constant, Λ, depends on both the radionuclide and source model, and is 
influenced by the source encapsulation’s internal design. The definition of the dose-rate constant 
in water is the ratio of dose rate at the reference position to SK : 
       (1.2) 
 
 The radial dose function, g (r), accounts for dose fall-off on the transverse-plane due to 
photon scattering and attenuation, and is defined as:   
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(1.3) 
 
 
At the reference point, the radial dose function is equal to unity.   
The 2D anisotropy function, F(r, θ), describes the variation in dose due to self-absorption 
of radiation as a function of polar angle relative to the transverse plane.   
  
(1.4) 
 
At the reference point, the anisotropy function is equal to unity.   
Physically, the geometry function, G(r, θ), neglects scattering, attenuation, radionuclide 
energy spectrum, and accounts for the inverse square dose fall off and distribution of radioactive 
material inside the radioactive source on the dose distribution at a given point. 
 
      (1.5) 
 
 
where L is the length of the radioactive source, and β is the angle subtended by the radioactive 
source with respect to the point of interest. 
1.3.2 Deterministic Method:  Monte Carlo Technique 
The transport of radiation through matter is a stochastic process and can be simulated 
modeling physical law combined with the probabilities of interactions.  For this type of 
application, a MC simulation is based on a repeated random sampling of particle histories to 
simulate random trajectories of individual particles.  A single history finishes when the primary 
particle and all its liberated secondary particles lose enough energy that the remainder is 
considered negligible.  Each history serves as an independent sample contributing towards the 
simulation result or tally, which is a statistical estimate of an actual dose distribution.  When 
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enough histories are simulated, the central limit theorem applies and accurate dosimetric 
information on the transport process may be obtained by averaging over the entire simulation 
tally.  Also, Strong’s theory of large numbers says that results obtained from a large set of trials 
should be close to the expected value, and will tend to become closer as more trials are 
performed.  Applications of MC techniques in medical physics, especially radiation therapy 
physics, have been discussed in numerous publications [8-10].  MC is considered the “gold 
standard” for dose computation accuracy once its application has been validated experimentally.   
To accurately simulate a dose distribution using MC, the user must correctly model the 
geometry of the problem.  The MC input file contains information about the geometry and 
material specification; the location and characteristics of the source; and any type of answers or 
tallies applicable.  MC is able to simulate photon interactions such as the photoelectric effect, 
characteristic x-rays, coherent scattering, Compton scattering, and pair production [11].   
Serial computation of millions of histories involves a significantly large amount of 
computing time.  The MC calculation time is affected by the solid-angle effect and inverse-
square law fall off of the radiation from the radioactive source since they result in fewer 
simulated photons at a distance away from the source.  According to the central limit theorem, 
the relative error is proportional to 1/√ , where N is the number of histories; and is used as a 
surrogate for computational time.  The serial MC method requires long calculation times to 
generate dose distributions with satisfactory statistical uncertainties.  To circumvent long 
computation times, MC parallel processing is able to simulate and track particle histories 
independently and simultaneously; the histories can be separated into several batches and 
executed in parallel.  As of 2010, the Monaco TPS version 2.03 is the only commercially 
available MC-based treatment planning system for EBRT. 
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1.4 ICBT Applicators and Their Dosimetric Effect 
Unfortunately, current clinical TPS are typically unable to accurately account for the 
dosimetric effects of additional source encapsulation, such as polysulfone and high-Z shielding, 
provided by the applicator in certain HDR ICBT techniques.  These TPS systems utilize the TG-
43 algorithm which does not provide a method to quantify the attenuative effects when 
calculating dose.  The TG-43 formalism assumes calculations are in water.   As such, errors of 
5% - 30% or more may occur in planned dose to OARs [12-13].  Also, brachytherapy applicators 
which produce a non-cylindrically symmetric dose distribution cannot be incorporated into the 
TG-43 2D formalism.   
One way to account for these dose perturbations is through the use of the MC technique.  
But, due to the intense computational time requirements for MC dose calculations, clinical use of 
MC for ICBT treatment planning is impractical.  Investigations have been made into the use of 
pre-calculated MC data sets which characterize common brachytherapy dose distributions which 
are then applied to patient-specific geometries [14-15].  The technique presented by Rivard et al. 
(i.e. the Tufts technique) treats the brachytherapy applicator as an additional source 
encapsulation and employs MC to generate new TG-43 2D relative parameters (i.e. radial dose 
function,  anisotropy function) specific to the radioactive source and brachytherapy applicator 
combination [15] which is then implemented into the TG-43 2D dose calculation.  The TPS is 
then able to generate a 3D dose distribution that incorporates the applicator’s attenuative effect 
into superposition calculations using MC-generated dose distribution parameters.  However, this 
technique is only applicable to brachytherapy applicators that deliver a cylindrically symmetric 
dose distribution as TG-43 methods are limited to 2D.    
Price et al. developed a rudimentary TPS that utilized pre-calculated MC data sets to 
simulate patient ICBT treatments delivered using a shielded tandem and ovoid applicator [16].  
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Because the system determined total dose to the patient through the superposition of dose 
distributions resulting from individual source dwells, a large number of MC simulations were 
required for commissioning.  The systems required, as input, a simulated distribution for each 
possible source dwell-position, for each ovoid (left and right), for all possible ovoid lateral 
separations.  As such, robust commissioning of the system was time prohibitive when one 
considers that for acceptable accuracy, a simulation of a few hundred million histories is required 
for each possible source position.  In spite of these shortcomings, when commissioned with 
limited data applicable to a specific patient geometry, Price et al. reported a 94% agreement in 
dose to a clinically-applicable volume for a simulated patient treatment when compared to an 
equivalent volume whose ICBT delivered dose was simulated explicitly using MC techniques.  
The benefit of Price et al.’s system was in that their results were obtained nearly 5000 times 
faster than explicit MC system modeling and simulation.  To reduce the commissioning 
requirements and extend the practicality of Price’s system, the minimum amount of 
commissioning data required to produce a clinically viable pre-calculated MC-based TPS for 
ICBT must be determined.   
In this work we present a modification to the method of Price et al. that, rather than 
employing pre-calculated MC data sets directly for dose determination, implements MC-based 
correction factors that correct for shortcomings intrinsic to TG-43 methods (more detailed 
discussion on correction factors in Chapter 2).  When applied to TG-43 calculated dose, these 
correction factors will account for any dosimetric effects due to the presence of ICBT applicators 
during treatment delivery.  The motivation driving this modification is that it facilitates the 
method’s integration into existing, commercially-available TPS.  Additionally, it is thought that 
by taking into account the dominant dosimetric effects of inverse-square falloff of dose with 
distance from the source (via TG-43 methods) as well as the attenuative effects of the ICBT 
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applicator (via MC-correction factors), an accurate patient dose calculation can be made while 
by-in-large ignoring the secondary influence of scatter due to tissue inhomogeneities.  However, 
verifying this expectation is beyond the scope of the presented work. 
1.5 Hypothesis and Specific Aims 
 A 3D Monte Carlo-simulated dose distribution of the ovoid contribution to a cervical 
intracavitary brachytherapy (ICBT) treatment administered via Nucletron’s Fletcher CT-MR 
ovoid applicator (Nucletron Corporation, Veenendaal, The Netherlands), modeled with and 
without a rectal shield surrogate, will agree, within criteria, with the dose distribution resulting 
from an equivalent treatment calculated using AAPM Task Group-43 (TG-43) methodology 
when corrected for heterogeneities using pre-calculated MC correction factors applied (a) to 
individual source dwell-positions and (b) individual ovoids acting as multi-source surrogates for 
varying adjacent dwell-time gradients (∇dt).  Criteria are defined as agreement within +/- 2% 
dose or +/- 2 mm distance-to-agreement (DTA).   
Three aims have been completed to test this hypothesis: 
1.5.1 Aim 1.  Confirm a Monte Carlo Model of A Paired Nucletron Fletcher CT-MR Ovoid 
Applicator. 
 A Monte Carlo (MC) model of the Nucletron high-dose rate (HDR) ICBT CT-MR 
compatible Fletcher ovoid set will be created and experimentally confirmed via film dosimetry.  
Absolute dose measurements will be made in two perpendicular planes, (a) 1 cm beyond the 
distal end and (b) 3.3 cm from, and parallel to, the long axis of a single ovoid.  Measurements 
will be carried out in water. 
1.5.2 Aim 2.  Create a Library of 3D Correction-Attenuation Matrices.   
 Two MC models will be used to simulate 3D dose distributions in water for clinically 
relevant microSelectron HDR (mHDR) Ir-192 dwell-positions.  The two MC models will model 
(1) the commercially-available CT-MR compatible Fletcher ovoid confirmed in Aim 1 and (2) a 
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modified version of that includes a high-Z heterogeneity acting as a rectal shield surrogate.  
These distributions will take into account source loading geometry as well as dose perturbations 
due to the ovoids.  From this data, a library of 3D attenuation-correction matrices will be 
developed that characterize the dosimetric effect of the commercial ovoid as well as the modified 
ovoid model to create both source- and ovoid-based correction factors. 
1.5.3 Aim 3.  Apply Attenuation-Correction Matrices To Treatment Planning System-
Calculated Dose Distributions And Compare To Monte Carlo Calculations.   
 The two sets of ovoid and source-based correction attenuation matrices will be applied to 
3D dose distributions calculated by the Oncentra Brachytherapy treatment planning system, 
which utilizes TG-43 dose-calculation methodology, in an attempt to reproduce MC-simulated 
dose distributions of equivalent treatment geometries.  The two sets of correction factors will be 
applied to different plans varying the ∇dt of each ovoid.  Agreement criteria will be applied and 
the hypothesis will be tested. 
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Chapter 2 Methods and Materials 
2.1 Aim 1:  Monte Carlo Confirmation Method 
 For Monte Carlo (MC) modeling of the Ir-192 high dose-rate source and ICBT applicator 
ovoids, Monte Carlo N-Particle eXtended (MCNPX) transport code was employed.  This MC 
package is capable of simulating transport of a variety of particles in complex, three dimensional 
geometries [11].  The validated MC model of the microSelectron v2 HDR (mHDR v2) Ir-192 
source (Nucletron Corporation, Veenendaal, The Netherlands) presented by Price et al. is 
utilized for all source simulations within this study and its design and material description can be 
found in their work [7].  Price et al. showed that MC simulated dose for a medial plane with 
effects from a high-Z shield was in agreement with radiochromic film measurements for 91% of 
the comparison points within +/-2% or +/- 2mm and approximately 98% were within +/-10% or 
+/-2mm distance-to-agreement (DTA) [17]. 
2.1.1 Nucletron CT-MR Compatible, ICBT Ovoid MC Modeling 
Detailed physical measurements of Nucletron’s CT-MR compatible tandem and ovoid 
applicator were performed in-house to facilitate construction of a MC model of the device.   The 
model consists of an ovoid set and does not include the intrauterine tandem.  The tandem was 
excluded due to its cylindrical symmetry and thin wall (≈ 1 mm) construction of nearly tissue 
equivalent material.  As such, dose calculated using TG-43 based or MC methods in a 
heterogeneous volume differ within the uncertainty of the MC calculation method. 
To ensure dosimetrically accurate simulations, it is important to model the entire physical 
system with sufficient precision when utilizing MC methods.  Therefore, the model used for this 
study included a paired of left and right ovoids that can house the mHDR v2 Ir-192 source in a 
variety of clinically applicable dwell-positions.  For this work, dwell-positions were limited to 
four (4) per ovoid with a separation of 5 mm between possible source positions.  Although only 
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one ovoid can be “active” (i.e. contain the stepped radioactive source) at any one time, all 
simulations included its “inactive” pair as it has been shown that dose discrepancies up to 14% 
may result when the inactive ovoid is not explicitly modeled [16].  This effect is especially true 
for shielded applicators.  The material, density, and composition of each component of the MC 
model used within this study are shown in Table 2.1.  A two-dimensional graphical 
representation of the study’s MC model is shown in Figure 2.1 (a) through (c). 
A few geometric features of the components were simplified to reduce the complexity of 
the MC input file while maintaining dosimetric accuracy at relevant clinical distances from the 
ovoid surface.  These include: (1) omitting the long handle of each ovoid, (2) approximating the 
retaining screw as a cylinder, (3) simplifying the shape of the intrauterine tandem flange spacer, 
(4) approximating the curvature of the colpostat shaft as two intersecting cylinders, and (5) 
modeling a length of 2 cm to approximate the braided steel cable attached to the proximal end of 
the mHDR v2 Ir-192 source.  It is also assumed for simulations that the mHDR v2 Ir-192 source, 
when deployed from the after loader, lays exactly along the central shaft of the ovoid.  As the 
nominal inner diameter of the source lumen within the ovoid shaft is 3.5 mm, the modeled 
source, which has a 0.9 mm outer diameter, could be off center by, at most, 1.3 mm [16].  
Assuming inverse square is the predominate effect; the uncertainty of absolute dose, directly 
adjacent to the ovoid, may be affected by the source being off center. 
The superposition of simulated dose matrices of individual Ir-192 source dwell-positions 
is required due to the density of the iridium source causing large anisotropy effects when sources 
are simulated simultaneously.  Multiple dwell-positions simulated simultaneously are not an 
accurate representation of an actual loaded HDR ICBT treatment where a single source is 
positioned at varying dwell points within the ovoid shaft at different times. 
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Table 2.1:  Materials of structures used in the CT-MR Fletcher ovoid set Monte Carlo 
simulations, their compositions listed by weight and density.  Dry air is defined at sea level (1 
atm) and 20º C. 
Structures Material 
Composition 
(% by weight) 
Density (g cm
-3
) 
Source encapsulation, 
braided steel cable 
AISI 316L stainless 
steel, conductor 
a
 
Mn 2.0 
Si 1.0 
Cr 17.0 
Ni 12.0 
Fe 68.0 
8.02 
4.81
a
 
Film phantom Liquid water H 11.2 
O 88.8 
1.0 
Ovoids Polysulfone C 66.0 
O 22.0 
S 7.4 
H 4.6 
1.29 
Outside of water 
phantom, interior of 
ovoid, interior of 
ovoid shaft, canal 
where retaining screw 
is fitted 
Dry air gas = 1
 b
 C 0.0124 
N 75.5267 
O 23.1781 
Ar 1.2827 
1.205 x 10
 -3
 
Radioactive source Iridium-192 Ir 100 22.42 
a Braided steel cable density is 4.81 g • cm-3 
b 
Gas state defined on material card in MCNPX 
 
2.1.1.2 The 
192
Ir Energy Spectrum 
The mHDR Ir-192 source has a half-life of 73.83 days and an average energy of 0.38 
MeV.  It decays by emitting beta particles and gamma radiation.  It is produced by neutron 
activation of iridium metal in a nuclear reactor.  The energy spectrum utilized for 
192
Ir source 
simulations is that reported by Glasgow and Dillman[18].  They reported that gamma and x-rays 
of energies less than 11.3 keV cannot penetrate through the high-Z source encapsulation and 
should not be included in the determination of the total specific gamma-ray constant, total 
specific x-ray constant, and total exposure rate constant.  The total number of photons emitted 
per disintegration was determined to be 2.32 by Price et al. [7].  This factor was used to convert 
the MC dose rate estimate per photon to the dose rate estimate per source contained activity in 
Equation 2.1. 
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                  (a)                                                                     (b) 
 
                                                                     (c) 
Figure 2.1:  Two-dimensional plots of the CT-MR Fletcher ovoid applicator set 
using the MCNPX graphical plotter through a.) the ZX-plane bisecting the ovoid 
shaft, b.)  the ZY-plane bisecting the ovoid shafts in the left/ right ovoids and      
c.)  the XY-plane bisecting the ovoid shaft.  Colors show different materials 
where blue, yellow, and red are water, Polysulfone, and air, respectively.   
 
2.1.1.3 The Tally Type, Mesh Size, and Relative Error of MC Dose Estimates 
The MCNPX “mesh” tally (F6:photons) type was utilized for study simulations.  The 
tally size for this study was a 10 x 10 cm
3
 plane with 1 mm
3
 voxels.  The type of tally utilized in 
this study scores the average energy deposition per unit volume (MeV cm
-3
 particle
-1
).  Tracked 
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particle interactions were limited to photons as the energy deposition for non-tracked secondary 
particles (i.e., electrons) was assumed to be constrained to within close proximity of the collision 
site [11].  Since secondary particles from low energy photons have a relatively short path length, 
compared to the voxel size, this tally yields a good approximation of collision kerma [16, 19-21].  
The normalization is per unit cell volume, not per unit mass, since the mesh cell may cover 
regions of different masses.   
Due to the inverse-square law fall off of emitted radiation, voxels far from a simulated 
source will record fewer histories compared to those more proximal.  For each tally voxel, MC 
reports an estimation of relative error, R, corresponding to one estimated standard deviation.  
The relative error is proportional to 1/√ , where N is the number of particle histories.  
Therefore, relatively large number of particle histories must be simulated in order to obtain 
energy depositions of acceptable error.  Since MC estimates of collision KERMA depend largely 
on simulated interaction cross-section data, the accuracy of these libraries plays an important role 
in the validity of simulated interactions.  As such, all cross-section libraries utilized in this work 
have been vetted by Los Alamos National Laboratory [11].  Finally, an additional source of error 
may lie within the inaccuracies of modeled geometries.  If errors exist in any of these study 
components (modeled geometry, energy spectrum, and interaction cross-section) disagreements 
will exist between simulated and measured dose distributions.  Therefore, film measurements 
have been performed to confirm the accuracy of the MC modeling of the ovoids.   
2.1.1.4 Conversion of MC Calculated Quantities to Absolute Dose 
 MCNPX mesh tally simulations are recorded as units of energy deposition per unit 
volume per simulated particle [MeV cm
-3
 particle
-1
].  To convert to absolute dose rate per 
contained activity, a method presented by Price et al. (2005) is utilized: 
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(2.1) 
 
 
 
Defining terms that are not simple conversions, 2.324 particles disintegration
-1
 is 
determined from the source spectrum utilized for MC simulations [18].  The conversion factor of 
1.13 contained to apparent activity was determined by Price et al. 2005.  A 1-Ci apparent activity 
of an encapsulated radioisotope source is defined to be the amount of encapsulated source that 
gives rise to the same exposure in air as an unencapsulated source of the same isotope of 1-Ci 
(contained) activity.  The definition of 0.243 mCi ≡ 1 μGy m2 h-1 defines the relationship of Sk to 
apparent activity for Ir-192 [1, 19].   
 To calculate the absolute dose per dwell-position for an ICBT HDR administration, 
Equation 2.2 was used: 
 
(2.2) 
 
where t[min] is the active dwell-time.  The conversion factor for air kerma strength to apparent 
activity for an Iridium-192 source is 0.243 mCi U
-1 
[1].   
2.1.2 Radiochromic Film Model Confirmations 
For model confirmation, the mHDR v2 
192
Ir source was positioned at three dwell-
positions within the colpostat and films were exposed in two perpendicular orientations.  
Radiochromic film (RCF) was utilized for this work due to its high spatial resolution, minimal 
energy dependence, insensitivity to ambient light, its ability to be immersed in water and near 
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tissue equivalence [22].  RCF consists of a thin (7 - 23 µm), radiosensitive layer of monomer 
crystals, dispersed in gelatin, bonded to a Mylar base [1]. When high-energy radiation interacts 
with the active layer, the monomer is polymerized, increasing the saturation of the dye’s color in 
proportion to the amount of radiation absorbed.  Gafchromic dosimetry media type MD-55-2 
(International Specialty Products Technologies, Wayne, NJ) radiochromic film (Lot # 
R0419MDV2) was used for MC model confirmation of the CT-MR ovoid applicator set in a 
liquid water phantom.  Since dose distributions in water were required for this MC model 
confirmation, the ability to submerge the film in water and to handle film in room light greatly 
simplifies the setup process.  According to the vendor, RCF is suitable for dose measurements 
within the range of 3 to 100 Gy.  The American Association of Physicists in Medicine (AAPM) 
has published detailed characteristics of this type of film and their suggested film handling 
recommendations were followed [22].  
2.1.2.1 Film Calibration  
A single calibration curve was used to calibrate films from the same manufacturing lot.  
Calibration curves were determined using 13 measurements acquired using 2 x 2 cm
2
 pieces of 
film cut from a single sheet.  The same corner of each individual pieces of film were marked in 
order to allow consistent, identical film orientation for film digitization [22].  Films were 
calibrated by placing the film perpendicular to an en face 4 MV beam set to 100 cm source to 
axis distance (SAD), placing 10 cm of Plastic Water on top of the film with 5 cm below for 
sufficient backscatter.  The pieces of film were then separately irradiated in the center of an open 
10 x 10 cm field to: 3, 5, 10, 23, 25, 28, 30, 33, 35, and 38 Gy.  One piece of film was not 
irradiated and used to provide the background / fog color saturation (optical density) level of the 
film.   
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As recommended by AAPM Task Group-55, irradiated RCFs were stored for at least 48 
hours prior to scanning to allow for film development under ambient conditions (temperature ≈ 
23
o
 C, relative humidity ≈ 30o C) with nominal exposure to fluorescent room lights. Irradiated 
films were digitized using an Epson Perfection V700 Photo flatbed scanner (Seiko Epson 
Corporation, Nagano, Japan). The 16-bit red channel image was exported for film analysis as the 
absorption peak of RCF film lies at ≈ 773 nm, which corresponds to the scanner’s red channel.  
A scanning resolution of 96 dpi (≈ 0.3 mm pixel-1) was used for film digitization.   
After digitization of the calibration films, Image J (Image J, Bethesda, Maryland) 
software was utilized to measure the average scanner value for a 1 cm
2
 region in the center of 
each film piece to correlate the scanner value to known dose values.  Image J freeware is a public 
domain image processing program that can be used for image analysis [23].  After plotting the 
scanner values vs. absorbed dose, a second order polynomial was fit to the resulting curve to 
convert film scanner values to absorbed dose as shown in Figure 2.2. 
 
Figure 2.2:  RCF measured calibration points used to convert RCF readings to 
dose.  
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2.1.2.2 Treatment Planning for Model Confirmation Film Irradiations 
 The Nucletron Corporation Oncentra brachytherapy treatment planning system 
(Veenendaal, The Netherlands) was used to determine the dwell-time required to deliver a 10 Gy 
to a point 1.7 cm away and perpendicular to the long-axis of a source positioned 5mm proximal 
and distal to, two adjacent dwell-positions (three dwell-positions total) (c.f. Figure 2.3).  An 
additional plan was constructed that determined dwell-times for three sources in an equivalent 
orientation that delivered 10 Gy to a point that lay 3.3 cm away and parallel to the long-axis of 
the middle dwell-position (c.f. Figures 2.3).  These points were selected to act as surrogates for 
the rectal and disease plane, respectively.  With air kerma strength of 32701 μGy m2 h-1, the 
resulting treatment plan for both planes called for indexer lengths of 1500 mm, 1495 mm, and 
1490 mm with a total dwell-time evenly distributed for all dwell-positions of 10.9 min and 18.3 
min for the rectal plane and disease plane, respectively. A radiograph was inspected to confirm 
source position / indexer length correspondence of the ovoid applicator set to the MC modeling 
of the source position within the ovoid. 
2.1.2.3 Phantom Film Measurement Setup 
 In-room patient setup lasers were used to align the colpostat shaft perpendicularly to the 
rectum surrogate film plane (c.f. Figure 2.3a) or parallel to the disease surrogate film plane (c.f. 
Figure 2.3b).  Films were placed atop slabs of Solid Water submerged within the water phantom.  
Room lasers were also used to carefully orient each film in a reproducible fashion.  Once 
properly aligned, the ovoid was attached to the mHDR afterloader (Nucletron, Veenendaal, The 
Netherlands) and plans were delivered.  Each plan was delivered three times to for a total of 6 
measurements. 
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Figure 2.3:  Monte Carlo model film confirmation phantom.  (a) The GafChromic 
film is shown in the “rectum plane” orientation.  (b) The GafChromic film is 
shown in the “medial plane” orientation.  The ovoid, water tank, and film were 
aligned using vault lasers. 
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2.1.2.4 Film Data Processing and Analysis 
The average of three measurements was acquired for each plane measured for the MC 
model confirmation.  The standard deviation, σ, between three measurements was calculated to 
compare pixel to pixel for each film.  
 MC confirmation RCF measurements were processed following the same methods 
utilized for RCF calibration.  All films were scanned in equivalent orientations and locations on 
the flatbed scanning window.  In-house software was developed using Matlab v7.8 (2007a, The 
MathWorks, Natick, MA) for all data processing.  The software was written to facilitate 
importation and processing of the digitized TIFF images as well as the conversion of raw image 
data (scanner values) to absorbed dose [Gy].  To reduce inherent image noise, an adaptive 2-D 
Wiener filter was applied to all scanned film data.  To perform an analysis, the algorithm first 
down-sampled the red channel of the TIFF image so as to spatially match the MC dose array and 
then registered the RCF film data to the MC simulated dose.  Software written in Matlab allowed 
incremental 1 mm shifts to the film data in the up, down, left, and right directions in order to 
spatially match the MC simulated dose.  Table 2.2 lists the uncertainty components associated 
with MC model confirmation film measurements.  An expanded uncertainty of 11% is the total 
uncertainty in measurements. 
Film measured dose distributions were compared to MC simulations to evaluate the 
dosimetric accuracy of the MC model.  The comparison consisted of determining the number of 
points within an arbitrary percent agreement as well as distance-to-agreement (DTA).  The 
algorithm selected a corresponding point from both data sets and determined whether or not the 
percent difference passed the dose criteria (e.g. 2%) using: 
 
(2.3) 
 
%,100
),(
),(),(
% 


jiMC
jiMCjiFilm
Difference
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where i and j are indexes used to define pixel location (row and column).  If this point is within 
the dose criterion, the algorithm continues to the next point in the data set.  If the point is not 
within criteria, the algorithm searches for a point within the distance criteria (e.g. 2 mm) for a 
value that meets the dose criteria.  This is repeated for all corresponding points in the MC and 
image data set.  An overview of this process is shown in Figure 2.4.   
Table 2.2:  Estimated relative uncertainties of the radiochromic film dose interpretations per 
measured unit reference air kerma rate. 
Uncertainty component Relative one standard uncertainty (%) 
Calibration of the 4MV LINAC  3.0 
Response of the film exposed to the LINAC 3.0  
Response of the films exposed to the source 
under test 
 3.0 
Sk calibration for source under test 1.67
 a 
Combined standard uncertainty  5.5 
Expanded uncertainty (k=2)  11 
a
Nucletron Certificate for Sealed Sources. 
 
Figure 2.4:  Illustration of comparison algorithm.  *Values below 3 Gy (as 
recommended by TG-55) are not included in the comparison.  **If one point 
passes the tolerance and distance condition, then point (x, y) passes. 
2.2 Aim 2:  Development of 3D Attenuation Correction Factor Database 
Two MC models will be used to simulate 3D dose distributions in water for clinically 
relevant mHDR Ir-192 dwell-positions.  The two MC models will model (1) the commercially-
available CT-MR compatible Fletcher ovoid confirmed in Aim 1 and (2) a modified version of 
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that includes a high-Z heterogeneity acting as a rectal shield surrogate.  A two-dimensional 
graphical representation of the study’s modified MC model is shown in Figure 2.5.  Because the 
CT/MR compatible Fletcher ovoids are not available in a shielded model, this modification was 
included in this study as a proof of principle for this correction scheme.  Clinical shielded ovoid 
applicators contain 1.7 mm tungsten “half discs” compared to the rounded distal end being 
comprised of metal.  Dose perturbations are expected to be significant with the modified shield 
as opposed with an actual clinically available shield.   
 
 
(a)        (b) 
Figure 2.5:  Two-dimensional plots of the modified CT-MR Fletcher ovoid 
applicator set using the MCNPX graphical plotter through a.) the ZX-plane 
bisecting the ovoid shaft, and b.)  the ZY-plane bisecting the ovoid shafts in the 
left/ right ovoids.  Colors show different materials where blue, yellow, green, and 
red are water, polysulfone, tungsten, and air, respectively.   
 
To create the MC attenuation-correction dataset libraries, a mesh tally (F6: photons), 10 x 
10 x 10 cm
3
 in size was used to tally energy deposition per particle within 1 mm
3
 voxels.  A total 
of eight source-dwell indexes: 1500 mm, 1495 mm, 1490 mm, and 1485 mm (measured from the 
afterloader port) for both right and left ovoids, were simulated.  The origin of each mesh tally 
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was positioned to coincide with the geometric center of the mHDR v2 Ir-192 source. All 
simulations were run for 260 x 10
6
 histories to achieve a statistical uncertainty of less than 2% at 
the most distant elements of the tally grid.  Due to the computing time required for simulations of 
this magnitude, a parallel-processing capable, super-computing cluster was used for these 
simulations.  The Tezpur super-computing cluster (Louisiana State University High Performance 
Computing Department) is a 360 node cluster able to perform 15.3 x 10
12
 floating point 
operations per second.  Since MC simulates and tracks every particle history independently, the 
histories can be grouped into several batches and executed in parallel.  A single 260 million 
history simulation (101 x 101 x 101, 1 mm
3
 tally voxels) ran parallel on 100 processors required 
approximately 10 hours.  To test the hypothesis, the following two methods were employed to 
calculate the attenuation-correction matrices. 
2.2.1 Method 1:  Ovoid-Based Correction Factor, cO 
The ovoid-based correction factors, cO, were calculated using: 
 
 
(2.4)  
 
 
where   
          is dose rate per activity [Gy mCi-1 hr-1] to a voxel centered at (x, y, z) in the 
experimental coordinate system converted from MC-calculated energy deposition per particle 
using equation 2.1 and    
            is the  dose rate per activity [Gy mCi-1 hr-1] to a voxel of 
an equivalent position, in the same coordinate system, as calculated by the TPS using AAPM 
Task Group 43 methodology [6].  The index, O, is equal to either 1 or 2, indicating the 
handedness of the ovoid, patient right or left, respectively.  Both   
  and    
     consist of the 
superposition individual dose distributions of multiple dwells in each colpostat and the origin of 
these matrices is defined to coincide with the most distal source-dwell-position (active) within 
the corresponding ovoid: 
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(2.5) 
 
 
where   
             is dose rate per activity to a voxel centered at (x’,y’,z’) in the Monte Carlo 
coordinate system converted from MC-calculated energy deposition per particle using equation 
2.1 for a single dwell-position.  The index, s, corresponds to the dwell-position of the source 
within the ovoid (i.e. s = 1 (1500 mm), s = 2 (1495 mm), etc.).  Dwells 1 < s < 4 and 5 < s < 8 are 
contained within the patient right and left ovoids, respectively. Provisions are made for clinical 
applications that utilize both three (dwell-positions: s = 2 (1495 mm), s = 3 (1490 mm), and s = 4 
(1485 mm)) and four (dwell-positions: s = 1 (1500 mm), s =2 (1495 mm), s = 3 (1490 mm), and 
s = 4 (1485 mm)) inter-colpostatic dwells as both are common practice (i.e. 3 vs. 4 distributions 
superimposed when calculating   
  ).    
           , is the superposition of four dose 
distributions for a single ovoid.  This superposition is performed within the Oncentra TPS and 
the origin of this distribution is defined to be in the geometrical center of the right or left ovoid 
as a function of O within the experimental coordinate system.  For the calculation of both    
   
and   
    , source dwells were assumed to be coplanar, centered within the ovoid shaft, with the 
geometric center of each source located at is corresponding dwell-position index (e.g. 1500 mm).   
2.2.2 Method 2:  Source-Based Correction Factor, cS 
The source-based correction factors, cS, were calculated using (Equation) 
 
 
(2.6) 
 
 
where    
          is dose rate per activity [Gy mCi-1 hr-1] to a voxel centered at (x, y, z) in the 
experimental coordinate system converted from MC-calculated energy deposition per particle 
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using equation 2.1 for a single dwell-position and    
            is the  dose rate per activity [Gy 
mCi
-1
 hr
-1
] to a voxel of an equivalent position, in the same coordinate system, as calculated by 
the TPS using AAPM Task Group 43 methodology for a single dwell-position [6].  The index, s, 
is equal to values of 1 to 8, indicating the source position within of the ovoid (dwells 1 < s < 4 
and 5 < s < 8 are contained within the patient right and left ovoids, respectively).  Each   
   dose 
distribution’s origin is defined to coincide with the origin of the corresponding    
    . 
2.2.3 Analysis Software Development 
 In-house software was developed using Matlab v7.8 (2007a, The MathWorks, Natick, 
MA) for all data processing.  The software was written to facilitate importation, processing, and 
analyzing the dose data sets generated by the TPS, MC, and correction procedure (utilizing 
equations 2.3-2.6).  The data sets were analyzed using a 3D distance-to-agreement algorithm, 
which is illustrated in Figure 2.5.  The algorithm selects a corresponding point from two data sets 
and determines whether the percent error passes within the dose criteria (i.e. 2% tolerance).  If 
this point is within the dose criterion, the algorithm continues to the next point in the data set.  If 
the point is not within criteria, the algorithm searches for a point within the distance criterion 
(i.e. 2 mm) for a value which passes within the dose criteria (i.e. 2% tolerance).  This is repeated 
for all points in the two data sets.   
2.3 Aim 3:  Application of 3D Correction Strategy to Patient Cases 
2.3.1 DICOM 
 Digital Imaging and Communications in Medicine (DICOM) network protocol is a 
standard that is a framework for handling, storing, printing, and transmitting medical-imaging 
data [1].  The standard was developed in 1983 by the American College of Radiology (ACR) and 
the National Electrical Manufacturers Association (NEMA) with input from various vendors, 
academia, and industry groups.  DICOM was developed as response to the need of a standard 
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method for transferring images and related information between devices from different 
companies.  DICOM provides standardized formats for images, a common information model, 
application service definitions, and protocols for communication.  DICOM is useful in storing 
and organizing radiotherapy plans because it groups information into data sets.  For example, a 
DICOM file stores image data (i.e. CT image) and patient information (i.e. name, patient 
number, image type) within one file, so that the image can never be separated from the  
 
Figure 2.6:  Illustration of 3D dose tolerance and distance-to-agreement 
algorithm.  A point must pass the dose tolerance criteria or have another point 
within the distance criteria which is within the dose tolerance, in order for (x, y) 
to pass. 
information by mistake. Oncentra uses the DICOM 3.0 standard for storage of the image data.  
Oncentra exports three DICOM compliant files: (1) the DICOM Radiotherapy Plan (RP) file, (2) 
the DICOM Radiotherapy Dose (RD) file, and (3) the DICOM Radiotherapy Structures (RS).  
2.3.2 Application of Correction Factors to TPS-Calculated Plans 
2.3.2.1 Attenuation-Correction Factor Calculation for Method 1 
 The TPS corrected dose [Gy] to a point located at (X, Y, Z) in the patient coordinate 
system was calculated using: 
 
(2.7) 
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where TPS
Od is the superimposed ovoid-source surrogate dose distribution of either the left or right 
ovoid (O=1 represents left ovoid and O=2 represents right ovoid) generated using Oncentra TPS.  
The coordinate system of the ovoid-correction matrix, cO, was translated using MATLAB to 
register and coincide with the TPS coordinate system (i.e. X, Y, Z) before it was applied.  Two 
correction matrices were applied to correct the exported TPS plan. 
2.3.2.2 Attenuation-Correction Factor Calculation for Method 2 
The TPS corrected dose [Gy] to a point located at (X, Y, Z) in the patient coordinate system was 
calculated using: 
 
(2.8) 
 
 
 
where TPS
Sd is the source dose distribution of dwell index S (S=1-4 represents indexes within left 
ovoid and S=5-8 represents indexes within right ovoid) generated using Oncentra TPS.  The 
coordinate system of the source-correction matrix, cS, was translated using MATLAB to register 
and coincide with the TPS coordinate system (i.e. X, Y, Z) before it was applied.  Eight 
correction matrices were applied to correct the exported TPS plan. 
2.3.3 Case Selection 
 Three-dimensional planning for brachytherapy treatments requires modeling the patient 
anatomy utilizing a set of 2D images that represent a patient’s anatomy in 3D, localizing the 
dwell-positions in 3D, calculating appropriate dwell-times, and finally simulating the dose 
distribution for the specified geometry.  Treatment planning refers to the quantitative parts of the 
process by which the individualized patient treatment plan is determined.   
 Dwell-positions in a co-planar geometry were exported using Oncentra TPS, and several 
dwell-time combinations were investigated to test the hypothesis.  This geometry was chosen 
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because (1) the same geometry for dwell-position coordinates could be specified in the MC 
coordinate system and (2) the voxel size was set to be equivalent to the MC models. 
2.3.3.1 Maximum Adjacent Dwell-Time Gradient 
Dwell-positions can be described according to their dwell-time as a relative difference known as 
the dwell-time weighting factor, wn.  The wn was calculated by using: 
(2.9) 
 
 
where tn is the dwell-time at index “n” and Ttotal is the total dwell-time.  The wn ranges from zero 
to one (i.e. [0, 1]).  A value of zero means that the dwell-time for that dwell-position is zero.  
 The adjacent dwell-time gradient, ∇dt, was calculated for every dwell-position by using: 
 
(2.10) 
 
This equation determines the difference between adjacent wn.  Calculations with a wn of zero are 
ignored if that dwell index represents the distal or proximal end of the catheter. 
Each comparison case was described by its maximum ∇dt.  Several ∇dt (i.e. 0, 0.3, 0.6, 
0.7) were used to analyze the effectiveness of both attenuation-correction factor methods.  For 
every case, a comparison of the TG-43 calculation to the MC simulation was made utilizing the 
3D DTA algorithm for both ovoid- and source- based attenuation correction factors.   
2.3.4 Analysis 
 Several dwell-time weighting differences were used to test the hypothesis.  Each plan was 
compared to its corresponding superimposed MC dose distribution to quantify the differences 
due to the presence of the applicator ovoids.  Also, the dose distribution resulting from both MC 
models were compared to both corrected TPS plans (ovoid-based and source-based).  
Comparisons were made by determining the percentage of points which agree within 2% or 2mm 
DTA.  
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Chapter 3 Results and Discussion 
3.1 Aim 1:  MC Modeling of a Nucletron ICBT CT-MR Fletcher Ovoid Applicator  
3.1.1 Model Confirmation via Radiochromic Film 
 A comparison of radiochromic film (RCF) measurements and Monte Carlo (MC) 
simulated absolute dose in water for two perpendicular planes in water are shown in Figures 3.1 
– 3.2.  Three independent RCF measurements were averaged, for both the “rectum” surrogate 
and “disease” surrogate planes, and then spatially registered to the corresponding MC data set for 
comparison.  To register these data sets, software written in Matlab which shifted the dataset by 
1 mm in the up, down, left, and right direction.  Since the water phantom setup did not allow for 
the RCF to be marked with respect to ovoid placement, registration was done visually in order to 
best match up the isodose lines.  Regions containing dose values less than 3Gy were not included 
in RCF/MC comparisons per AAPM Task Group Report 55.  
Qualitatively, one observes fair agreement of equivalent isodoses for compared data.  
Quantitatively, MCNPX tallied dose agreed to within +/- 2% or +/- 2mm for 96% of the points 
on the film acting as the “disease” surrogate and to within +/- 2% or +/- 2mm for 96% of the 
points on the film acting as the “rectum” surrogate.  The average standard deviation of the three 
“disease” surrogate and “rectum” surrogate RCF measurement datasets are 11+/- 7.4 cGy and 9 
+/- 7.0 cGy, respectively.  The “rectum” surrogate film had regional discrepancies at the high-
dose gradient region near the center.  This is possibly the result of the inverse square factor 
having a strong influence in regions close to the source.  The center point of the film was the 
closest distance between the film plane and source.  For MC, points farther from the center point 
of the mesh (i.e. simulated film) plane result in a larger distance to the source reduces statistical 
uncertainty.  The “disease” surrogate film was 3.3 cm away from the source, in contrast to the 
1.7 cm distance for the “rectum” plane, which results in less inverse-square influence.  These 
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results indicate that the models of the mHDR v2 Ir-192 source and paired ovoid component of 
Nucletron’s CT-MR compatible applicator MC model are robust enough to simulate dose 
distributions with sufficient accuracy within the context of this study. 
 
Figure 3.1:  Anterior rectal wall MC/RCF isodose contour comparison.  Comparison of 
MC (dashed) simulated and RCF (solid) measured dose, in cGy, for a plane located 1.7 
cm distal to the distal surface of a single ovoid.  This plane serves as a surrogate to the 
anterior rectal wall of a patient.  The simulation and measurements are for three (3) 
dwell-positions indexed 1500, 1495, and 1490 mm from the afterloader exit port for 
dwell-times of 1.2 minutes per source for an activity of 8.32 Ci.  Quantitatively, 96% of 
the comparison points are within +/- 2% or +/- 2mm. 
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Figure 3.2:  Lateral disease wall MC/RCF isodose contour comparison.  Comparison of MC 
(dashed) simulated and RCF (solid) measured dose, in cGy, for a plane located 3.3 cm 
lateral to the long-axis of a single ovoid.  This plane serves as a surrogate to the disease 
wall, lateral to the cervix, of a patient.  The simulation and measurements are for three (3) 
dwell-positions indexed 1500, 1495, and 1490 mm from the afterloader exit port for dwell-
times of 6.1 minutes per dwell for an activity of 8.32 Ci.  Quantitatively, 96% of the 
comparison points are within +/- 2% or +/- 2mm. 
 3.2 Aim 2:  Development of Ovoid and Source-Based Correction Factors  
3.2.1 Nucletron MicroSelectron High-Dose Rate Ir-192 Source 
Comparisons of MC-simulated isodose distribution and isodoses calculated using TG-43 
methodology for a single mHDR v2 Ir-192 source in water with a source activity of 10 Ci and 
dwell-time of 100 seconds is shown in Figure 3.3.  Observed in this figure are the qualitative 
differences in dose due to the different calculation methods and overlay of an Ir-192 source (not 
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to scale).  Quantitatively, 99.6% of the comparison points are within +/- 2% or +/- 2mm between 
MC and TG-43 for a single source in water.  The slight differences can be contributed to the 
high-dose, high-dose gradient region near the source. In the lateral direction (i.e. parallel to y 
axis), the isodose lines agree very well.  The dose distribution along the longitudinal axis (i.e. 
parallel to z axis) of the Ir-192 source is intrinsically anisotropic due to self-attenuation 
throughout the high-density cylindrical Ir-192 core, asymmetric steel jacket construction, and 
steel cable attached to one end of the source. With respect to the orientation of the mHDR v2 Ir-
192 source along its longitudinal axis, the forward direction for this comparison is –z direction 
and the backward direction (along the braided steel cable) is +z direction.  The MC simulation 
predicts equivalent dose when compared to the dose distribution calculated using TG-43 
calculations in the forward direction.  Dose differences in the backward direction (i.e. with 
respect to the longitudinal axis) can be a result of (1) the mathematical modeling error associated 
with TG-43 methodology, (2) the MC photon transport code overestimating the anisotropy 
factor, or (3) attenuation due to the 5 mm braided steel cable attached to the source.  Reviewing 
TG-43 source anisotropy factors utilized in the TPS, as expected, the dose distribution in the 
backward direction is relatively less than in the forward direction. Thus, AAPM TG-43 
methodology accounts for an asymmetric anisotropy factor due to the asymmetric source 
construction.  
3.2.2 Nucletron CT-MR Compatible Applicator 
Comparisons of MC-simulated isodose distribution and isodoses calculated using TG-43 
methodology for a single mHDR v2 Ir-192 source at multiple dwell indexes (e.g. dwell indexes 
1500 mm, 1495 mm, 1490 mm, and 1485 mm) within a Nucletron CT-MR compatible applicator 
in water (source activity of 8 Ci and dwell-time of 200 seconds) are shown in Figures 3.4 
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through 3.5.  Shown in Figure 3.6 illustrates the superimposed dose distributions which are used 
to create the ovoid- based correction matrix.  Observed in these figures are the qualitative 
  
Figure 3.3:  Comparison of MC (red dashed) and TG-43 (solid blue) dose distribution, 
in Gy, resulting from a single source in water with equivalent source activities and 
dwell-time.  Quantitatively, 99.6% of the comparison points are within +/- 2% or       
+/- 2mm.  The source is drawn to show perspective and is not drawn to scale.   
differences in dose due to the perturbing effects of the ovoid accounted for in MC simulations 
(dashed red lines) and unaccounted for in TG-43 calculations (solid blue line) for a single 2D 
plane at each dwell index.  Differences along the longitudinal axis of the source can be 
contributed to the air that is present within the ovoid shaft.  Quantitatively, >99% of the 
comparison points are within +/- 2% or +/- 2mm for all comparisons.  There are no appreciable 
differences between the MC simulations of each dwell index with an TG-43 calculation.  The 
dose distribution is not significantly affected due to the presence of the CT-MR compatible 
applicator.  
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           (a)          (b) 
 
Figure 3.4(a-b):  Comparison MC and TG-43 dose distribution for dwell index (a) 1500 mm and (b) 1495 mm, in Gy, within a plane 
bisecting the right ovoid, resulting from a single source with equivalent source activities and dwell-times.  The source (blue cylinder, 
not to scale) is illustrated within the ovoid to give perspective of placement.  These plots illustrate   
    and   
     which are used to 
create the source-based correction matrix.  Quantitatively, > 99% of the comparison points are within +/- 2% or +/- 2mm for both 
contour plots.   
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          (a)                  (b)    
Figure 3.5(a-b):  Comparison MC and TG-43 dose distribution for dwell index (a) 1490 mm and (b) 1485 mm, in Gy, within a 
plane bisecting the right ovoid, resulting from a single source with equivalent source activities and dwell-times.  The source (blue 
cylinder, not to scale) is illustrated within the ovoid to give perspective of placement.  These plots illustrate   
    and   
     which 
are used to create the source-based correction matrix.  Quantitatively, > 99% of the comparison points are within +/- 2% or +/- 
2mm for both contour plots.  
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Figure 3.6:  Comparison MC and TG-43 dose distribution for superimposed dwell 
indexes:  1500 mm, 1495 mm, 1490 mm, and 1485 mm, in Gy, within a plane bisecting 
the right ovoid, resulting from four source dwell-positions with equivalent source 
activities and dwell-times.  The source (blue cylinders, not to scale) dwell-positions are 
illustrated within the ovoid to give perspective of placements.  These plots illustrate 
  
    and   
     which are used to create the ovoid-based correction matrix.  
Quantitatively, 99% of the comparison points are within +/- 2% or +/- 2mm.   
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3.2.3 MC Applicator Modified to Include High-Z Inhomogeneities 
Differences between dose distributions resulting from the CT-MR compatible Fletcher 
ovoid applicator in water and TG-43 calculation for a single source in water agreed within the 
uncertainty of the MC simulation, a modification to include inhomogeneities within the MC 
model was introduced.  This high-Z modification was included in this study to test the robustness 
of the correction scheme.  Comparisons of MC-simulated isodose distribution and isodoses 
calculated using TG-43 methodology for a single mHDR v2 Ir-192 source at multiple dwell 
indexes (e.g. dwell indexes 1500 mm, 1495 mm, 1490 mm, and 1485 mm) within the MC model 
modified to include a high-Z inhomogeneities (source activity of 10 Ci and dwell-time of 300 
seconds) are shown in Figures 3.7 through 3.8.  These figures show the isodose distribution 
varies depending on which dwell-position is active.  Figure 3.9 is the superimposed dose 
distributions (i.e. all active dwell-positions) which are used to create the ovoid- based correction 
matrix.  Observed in these figures are the qualitative differences in dose due to the perturbing 
effects of the tungsten shield introduced in the MC simulations (dashed red lines) and 
unaccounted for in TG-43 calculations (solid blue line) for a single 2D plane.   
Quantitatively, < 17.1%, 39.9%, 81.8%, and 89.0% of the comparison points are within 
+/- 2% or +/- 2mm for dwell index 1500 mm, 1495 mm, 1490 mm, and 1485 mm, respectively.  
The superimposed dose distribution had an agreement of 21.8% of the comparison points 
agreeing within +/- 2% or +/- 2mm.  The dose distribution is significantly affected due to the 
presence of the tungsten shield.  Dose distributions resulting from dwell-positions near the 
tungsten shield (i.e. dwell indexes: 1500 mm, 1495 mm) are affected the most out of the four 
dwell-positions.  This is due to the Ir-192 source being contained within the high-Z metal.  
Primary photons, thus scatter radiation, in the path of tungsten are significantly reduced because 
of the high-Z attenuation.  
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           (a)          (b) 
 
Figure 3.7(a-b):  Comparison MC and TG-43 dose distribution for dwell index (a) 1500 mm and (b) 1495 mm, in Gy, within a 
plane bisecting the right ovoid, resulting from a single source with equivalent source activities and dwell-times.  The source (blue 
cylinder, not to scale) is illustrated within the ovoid to give perspective of placement.  The distal end (green) of the ovoid was 
modified to be tungsten with a density of 18 g/cm
3
.  These plots illustrate   
    and   
     which are used to create the source-
based correction matrix.  Quantitatively, 17.1% and 39.9% of the comparison points are within +/- 2% or +/- 2mm for dwell 
index 1500 mm and 1495 mm, respectively.   
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          (a)                  (b) 
Figure 3.8(a-b):  Comparison MC and TG-43 dose distribution for dwell index (a) 1490 mm and (b) 1485 mm, in Gy, within a 
plane bisecting the right ovoid, resulting from a single source with equivalent source activities and dwell-times.  The source 
(blue cylinder, not to scale) is illustrated within the ovoid to give perspective of placement.  The distal end (green) of the ovoid 
was modified to be tungsten with a density of 18 g/cm
3
.  These plots illustrate   
    and   
     which are used to create the 
source-based correction matrix.  Quantitatively, 81.8% and 89.0% of the comparison points are within +/- 2% or +/- 2mm for 
dwell index 1490 mm and 1485 mm, respectively.    
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Figure 3.9:  Comparison MC and TG-43 dose distribution for superimposed dwell 
indexes:  1500 mm, 1495 mm, 1490 mm, and 1485 mm, in Gy, within a plane 
bisecting the right ovoid, resulting from four source dwell-positions with equivalent 
source activities and dwell-times.  The source (blue cylinders, not to scale) is 
illustrated within the ovoid to give perspective of placements.  The distal end (green) 
of the ovoid was modified to be tungsten with a density of 18 g/cm
3
.  These plots 
illustrate   
    and   
     which are used to create the ovoid-based correction matrix.  
Quantitatively, 21.8 % of the comparison points are within +/- 2% or +/- 2mm.   
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3.3 Aim 3:  Application of Source- and Ovoid-Based 3D Correction Strategies 
3.3.1 Nucletron CT-MR compatible Fletcher Ovoid Applicator   
 Two coplanar ovoids were simulated with all four (4) dwell-positions per ovoid lying in 
the same plane.  Points lying within the ovoid, for both MC simulations and TG-43calculations, 
are not considered in comparison metrics as the dosimetry within the ovoids are of no clinical 
significance.  Dwell-time combinations were varied to test whether different dwell-time 
gradients affect the efficiency of either correction scheme.  Each plan was referenced according 
to the maximum dwell-time gradient (i.e. 0%, 5%, 10%, etc.) in the combination of dwell-times.  
A clinically applicable source activity of 8.7 Ci was used for all simulations.   
3.3.1.1 No Dwell-Time Gradient  
All dwell-times were equivalent and were set to 50 seconds.  Comparisons of MC-
simulated isodose distributions and isodoses calculated using TG-43 methodology is shown in 
Figure 3.10.  The CT-MR compatible Fletcher ovoid illustration is to convey the size and 
placement of the ovoid pair.  Although the plane bisects the source dwell-positions, the source is 
not illustrated.  Observed in this figure are the qualitative differences in dose due to the 
perturbing effects of the ovoids accounted for in MC simulations (dashed red lines) and 
unaccounted for in TG-43 calculations (solid blue line) for a single 2D plane.  Quantitatively, 
99.8% of the comparison points are within +/- 2% or +/- 2mm.  The differences between the two 
isodoses are within the uncertainty of the MC. 
Comparisons of MC-simulated isodose distributions and isodoses calculated using TG-43 
methodology that has been corrected using an ovoid-based correction factor is shown in Figure 
3.11a.  Observed in this figure are the qualitative differences in dose for MC simulations (dashed 
red lines) and ovoid-based corrected TG-43 plan (solid blue line) for a single 2D plane. 
Quantitatively, 100% of the comparison points are within +/- 2% or +/- 2mm.  There are no 
appreciable differences between the MC simulation and ovoid-based corrected TG-43 plan. 
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Next, comparisons for MC-simulated isodose distributions and isodoses calculated using 
TG-43 methodology that has been corrected using a source-based correction factor is shown in 
Figures 3.11b.  This figure illustrates the qualitative differences in dose for MC simulations 
(dashed red lines) and source-based corrected TG-43 plan (solid blue line) for a single 2D plane. 
Quantitatively, 100% of the comparison points are within +/- 2% or +/- 2mm.  Again, there are 
no appreciable differences between the MC simulation and source-based corrected TG-43 plan. 
 
Figure 3.10:  Comparison of MC simulation of a mHDR v2 Ir-192 source contained in 
a CT-MR compatible Fletcher ovoid applicator (red) vs. TG-43 calculations for a 
source in water (blue).  Maximum adjacent dwell-time gradient is zero.  Both ovoids 
are illustrated to show the plane and size of the ovoids.  Shown here are absolute dose 
comparisons, in Gy, for 8 dwell-positions (four per ovoid, dwell-position indices of 
1500, 1495, 1490, 1485 mm for each ovoid).  Quantitatively, 99.8% of the comparison 
points are within +/- 2% or +/- 2mm.   
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           (a)          (b) 
Figure 3.11(a-b):  Comparison of MC simulation of a mHDR v2 Ir-192 source contained in a CT-MR compatible Fletcher ovoid 
applicator vs. TG-43 corrected plans that account for applicator heterogeneities.  Maximum adjacent dwell-time gradient is zero.  
Shown here are 2D planes bisecting the ovoid pair comparing full MC calculations (red) and isodoses calculated using (a) ovoid-
based and (b) source-based corrected TG-43 plan (blue), in Gy, for 8 dwell-positions (four per ovoid, dwell-position indices: 
1500, 1495, 1490, 1485 mm for each ovoid).  Quantitatively, 100% of the comparison points are within +/- 2% or +/- 2mm for 
both comparisons.   
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3.3.1.2 Dwell-Time Gradient of 30% 
The dwell-times, keeping the same plan as previous, were manually set to 5 seconds for 
dwell index 1500mm, 7.5 seconds for dwell index 1495mm, 45 seconds for dwell index 
1490mm, and 67.5 seconds for dwell index 1485mm for both ovoids.  The maximum dwell-time 
gradient for this combination of dwell-times is 30%.   
Comparison of MC-simulated isodose distributions and isodoses calculated using TG-43 
methodology is shown in Figure 3.12.  The CT-MR compatible Fletcher ovoid illustration is to 
convey the size and placement of the ovoid pair.  Although the plane bisects the source dwell-
positions, and the source is only at a single location at any given time, the source is not 
illustrated.  Observed in this figure are the qualitative differences in dose due to the perturbing 
effects of the ovoids accounted for in MC simulations (dashed red lines) and unaccounted for in 
TG-43 calculations (solid blue line) for a single 2D plane.  Quantitatively, 99.7% of the 
comparison points are within +/- 2% or +/- 2mm.  The differences between the two isodoses are 
within the uncertainty of the MC. 
Comparisons of MC-simulated isodose distributions and isodoses calculated using TG-43 
methodology that has been corrected using an ovoid-based correction factor is shown in Figure 
3.13a.  Observed in this figure are the qualitative differences in dose for MC simulations (dashed 
red lines) and ovoid-based corrected TG-43 plan (solid blue line) for a single 2D plane. 
Quantitatively, 99.9% of the comparison points are within +/- 2% or +/- 2mm.  There are no 
appreciable differences between the MC simulation and ovoid-based corrected TG-43 plan. 
Next, comparisons for MC-simulated isodose distributions and isodoses calculated using 
TG-43 methodology that has been corrected using a source-based correction factor is shown in 
Figures 3.13b.  This figure illustrates the qualitative differences in dose for MC simulations 
(dashed red lines) and source-based corrected TG-43 plan (solid blue line) for a single 2D plane. 
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Quantitatively, 100% of the comparison points are within +/- 2% or +/- 2mm.  Again, there are 
no appreciable differences between the MC simulation and source-based corrected TG-43 plan. 
 
Figure 3.12: Comparison of MC simulation of a mHDR v2 Ir-192 source contained in 
a CT-MR compatible Fletcher ovoid applicator (red) vs. TG-43 calculations for a 
source in water (blue).  Maximum adjacent dwell-time gradient is 30%.  Both ovoids 
are illustrated to show the plane and size of the ovoids.  Shown here are absolute dose 
comparisons, in Gy, for 8 dwell-positions (four per ovoid, dwell-position indices of 
1500, 1495, 1490, 1485 mm for each ovoid).  Quantitatively, 99.7% of the comparison 
points are within +/- 2% or +/- 2mm.   
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           (a)          (b) 
Figure 3.13:  Comparison of MC simulation of a mHDR v2 Ir-192 source contained in a CT-MR compatible Fletcher ovoid 
applicator vs. TG-43 corrected plans of a source in water.  Maximum adjacent dwell-time gradient is 30%.  Shown here are 2D 
planes bisecting the ovoid pair comparing full MC calculations (red) and isodoses calculated using (a) ovoid-based and (b) source-
based corrected TG-43 plan (blue), in Gy, for 8 dwell-positions (four per ovoid, dwell-position indices: 1500, 1495, 1490, 1485 
mm for each ovoid).  Quantitatively, 99.9% and 100% of the comparison points are within +/- 2% or +/- 2mm for the ovoid-based 
and source-based corrected TG-43 plan, respectively.   
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3.3.1.3 Dwell-Time Gradient of 60% 
The dwell-times, keeping the same plan as previous, were changed to 5 seconds for dwell 
index 1500mm, 5 seconds for dwell index 1495mm, 35 seconds for dwell index 1490mm, and 
155 seconds for dwell index 1485mm for the left ovoid.  The right ovoid dwell-times were 
changed to 155 seconds for dwell index 1500mm, 35 seconds for dwell index 1495mm, 5 
seconds for dwell index 1490mm, and 5 seconds for dwell index 1485mm.  The maximum 
dwell-time gradient for this combination is 60%. 
Comparison of MC-simulated isodose distributions and isodoses calculated using TG-43 
methodology is shown in Figure 3.14.  The CT-MR compatible Fletcher ovoid illustration is to 
convey the size and placement of the ovoid pair.  Although the plane bisects the source dwell-
positions, and the source is only at a single location at any given time, the source is not 
illustrated.  Observed in this figure are the qualitative differences in dose due to the perturbing 
effects of the ovoids accounted for in MC simulations (dashed red lines) and unaccounted for in 
TG-43 calculations (solid blue line) for a single 2D plane.  Quantitatively, 99.0% of the 
comparison points are within +/- 2% or +/- 2mm.  The differences between the two isodoses are 
within the uncertainty of the MC. 
Comparisons of MC-simulated isodose distributions and isodoses calculated using TG-43 
methodology that has been corrected using an ovoid-based correction factor is shown in Figure 
3.15a.  Observed in this figure are the qualitative differences in dose for MC simulations (dashed 
red lines) and ovoid-based corrected TG-43 plan (solid blue line) for a single 2D plane. 
Quantitatively, 99.7% of the comparison points are within +/- 2% or +/- 2mm.  There are no 
appreciable differences between the MC simulation and ovoid-based corrected TG-43 plan. 
Next, comparisons for MC-simulated isodose distributions and isodoses calculated using 
TG-43 methodology that has been corrected using a source-based correction factor is shown in 
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Figures 3.15b.  This figure illustrates the qualitative differences in dose for MC simulations 
(dashed red lines) and source-based corrected TG-43 plan (solid blue line) for a single 2D plane. 
Quantitatively, 100% of the comparison points are within +/- 2% or +/- 2mm.  Again, there are 
no appreciable differences between the MC simulation and source-based corrected TG-43 plan. 
 
Figure 3.14:  Comparison of MC simulation of a mHDR v2 Ir-192 source contained in 
a CT-MR compatible Fletcher ovoid applicator (red) vs. TG-43 calculations for a 
source in water (blue).  Maximum adjacent dwell-time gradient is 60%.  Both ovoids 
are illustrated to show the plane and size of the ovoids.  Shown here are absolute dose 
comparisons, in Gy, for 8 dwell-positions (four per ovoid, dwell-position indices of 
1500, 1495, 1490, 1485 mm for each ovoid).  Quantitatively, 99.0% of the comparison 
points are within +/- 2% or +/- 2mm.  
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           (a)          (b) 
Figure 3.15(a-b):  Comparison of MC simulation of a mHDR v2 Ir-192 source contained in a CT-MR compatible Fletcher ovoid 
applicator vs. TG-43 corrected plans of a source in water.  Maximum adjacent dwell-time gradient is 60%.  Shown here are 2D 
planes bisecting the ovoid pair comparing full MC calculations (red) and isodoses calculated using (a) ovoid-based and (b) source-
based corrected TG-43 plan (blue), in Gy, for 8 dwell-positions (four per ovoid, dwell-position indices: 1500, 1495, 1490, 1485 mm 
for each ovoid).  Quantitatively, 99.7% and 100% of the comparison points are within +/- 2% or +/- 2mm for the ovoid-based and 
source-based corrected TG-43 plan, respectively.   
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3.3.1.4 Dwell-Time Gradient of 70% 
The dwell-times, keeping the same plan, were changed to 25 seconds for dwell index 
1500mm, 35 seconds for dwell index 1495mm, 2 seconds for dwell index 1490mm, and 150 
seconds for dwell index 1485mm for the left ovoid.  All dwell-times in the right ovoid were set 
to 25 seconds.  The maximum dwell-time weighting difference for this set is thus 70%. 
Comparison of MC-simulated isodose distributions and isodoses calculated using TG-43 
methodology is shown in Figure 3.16.  The CT-MR compatible Fletcher ovoid illustration is to 
convey the size and placement of the ovoid pair.  Although the plane bisects the source dwell-
positions, and the source is only at a single location at any given time, the source is not 
illustrated.  Observed in this figure are the qualitative differences in dose due to the perturbing 
effects of the ovoids accounted for in MC simulations (dashed red lines) and unaccounted for in 
TG-43 calculations (solid blue line) for a single 2D plane.  Quantitatively, 99.6% of the 
comparison points are within +/- 2% or +/- 2mm.  The differences between the two isodoses are 
within the uncertainty of the MC. 
Comparisons of MC-simulated isodose distributions and isodoses calculated using TG-43 
methodology that has been corrected using an ovoid-based correction factor is shown in Figure 
3.17a.  Observed in this figure are the qualitative differences in dose for MC simulations (dashed 
red lines) and ovoid-based corrected TG-43 plan (solid blue line) for a single 2D plane. 
Quantitatively, 99.9% of the comparison points are within +/- 2% or +/- 2mm.  There are no 
appreciable differences between the MC simulation and ovoid-based corrected TG-43 plan. 
Next, comparisons for MC-simulated isodose distributions and isodoses calculated using 
TG-43 methodology that has been corrected using a source-based correction factor is shown in 
Figures 3.17b.  This figure illustrates the qualitative differences in dose for MC simulations 
(dashed red lines) and source-based corrected TG-43 plan (solid blue line) for a single 2D plane. 
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Quantitatively, 100% of the comparison points are within +/- 2% or +/- 2mm.  Again, there are 
no appreciable differences between the MC simulation and source-based corrected TG-43 plan. 
 
Figure 3.16:  Comparison of MC simulation of a mHDR v2 Ir-192 source contained in 
a CT-MR compatible Fletcher ovoid applicator (red) vs. TG-43 calculations for a 
source in water (blue).  Maximum adjacent dwell-time gradient is 70%.  Both ovoids 
are illustrated to show the plane and size of the ovoids.  Shown here are absolute dose 
comparisons, in Gy, for 8 dwell-positions (four per ovoid, dwell-position indices of 
1500, 1495, 1490, 1485 mm for each ovoid).  Quantitatively, 99.6% of the comparison 
points are within +/- 2% or +/- 2mm.  
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           (a)          (b) 
Figure 3.17:  Comparison of MC simulation of a mHDR v2 Ir-192 source contained in a CT-MR compatible Fletcher ovoid 
applicator vs. TG-43 corrected plans of a source in water.  Maximum adjacent dwell-time gradient is 70%.  Shown here are 2D 
planes bisecting the ovoid pair comparing full MC calculations (red) and isodoses calculated using (a) ovoid-based and (b) source-
based corrected TG-43 plan (blue), in Gy, for 8 dwell-positions (four per ovoid, dwell-position indices: 1500, 1495, 1490, 1485 
mm for each ovoid).  Quantitatively, 99.9% and 100% of the comparison points are within +/- 2% or +/- 2mm for the ovoid-based 
and source-based corrected TG-43 plan, respectively.   
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3.3.2 MC Applicator Modified to Include High-Z Inhomogeneities 
The distal end of the ovoid material was converted to tungsten.  Points lying within the ovoids, 
for both MC simulations and AAPM TG-43calculations, are not considered in comparison 
metrics as the dosimetry within the ovoids are of no clinical significance.  Dwell-time 
combinations were varied so that different maximum dwell-time gradients were compared to test 
the hypothesis.  A clinically applicable source activity of 8.7 Ci was used for all comparisons.   
3.3.1.1 No Dwell-Time Gradient 
All dwell-times were equivalent and set to 50 seconds.  Comparisons of MC-simulated 
isodose distributions and isodoses calculated using TG-43 methodology is shown in Figure 3.18.  
The CT-MR compatible Fletcher ovoid illustration is to convey the size and placement of the 
ovoid pair.  Although the plane bisects the source dwell-positions, the source is not illustrated.  
Observed in this figure are the qualitative differences in dose due to the perturbing effects of the 
ovoids accounted for in MC simulations (dashed red lines) and unaccounted for in TG-43 
calculations (solid blue line) for a single 2D plane.  Quantitatively, 13.2% of the comparison 
points are within +/- 2% or +/- 2mm.   
Comparisons of MC-simulated isodose distributions and isodoses calculated using TG-43 
methodology that has been corrected using an ovoid-based correction factor is shown in Figure 
3.19a.  Observed in this figure are the qualitative differences in dose for MC simulations (dashed 
red lines) and ovoid-based corrected TG-43 plan (solid blue line) for a single 2D plane. 
Quantitatively, 100% of the comparison points are within +/- 2% or +/- 2mm.  There are no 
appreciable differences between the MC simulation and ovoid-based corrected TG-43 plan. 
Next, comparisons for MC-simulated isodose distributions and isodoses calculated using 
TG-43 methodology that has been corrected using a source-based correction factor is shown in 
Figures 3.11b.  This figure illustrates the qualitative differences in dose for MC simulations 
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(dashed red lines) and source-based corrected TG-43 plan (solid blue line) for a single 2D plane. 
Quantitatively, 100% of the comparison points are within +/- 2% or +/- 2mm.  Again, there are 
no appreciable differences between the MC simulation and source-based corrected TG-43 plan. 
 
Figure 3.18:  Comparison of  MC simulation of a mHDR v2 Ir-192 source contained in a 
modified CT-MR compatible Fletcher ovoid applicator to include a high-Z shield (red) 
vs. TG-43 calculations for a source in water (blue).  Maximum adjacent dwell-time 
gradient is zero.  Both ovoids are illustrated to show the plane and size of the ovoids.  
Shown here are absolute dose comparisons, in Gy, for 8 dwell-positions (four per ovoid, 
dwell-position indices of 1500, 1495, 1490, 1485 mm for each ovoid).  Quantitatively, 
13.2% of the comparison points are within +/- 2% or +/- 2mm.   
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           (a)          (b) 
Figure 3.19(a-b):  Comparison of  MC simulation of a mHDR v2 Ir-192 source contained in a modified CT-MR compatible 
Fletcher ovoid applicator to include high-Z shield vs. TG-43 corrected plans of a source in water.  Maximum adjacent dwell-time 
gradient is zero.  Shown here are 2D planes bisecting the ovoid pair comparing full MC calculations (red) and isodoses calculated 
using (a) ovoid-based and (b) source-based corrected TG-43 plan (blue), in Gy, for 8 dwell-positions (four per ovoid, dwell-
position indices: 1500, 1495, 1490, 1485 mm for each ovoid).  Quantitatively, 100% of the comparison points are within +/- 2% 
or +/- 2mm for both comparisons.   
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3.3.1.2 Dwell-Time Gradient of 5% 
The dwell-times, keeping the same plan, were manually set to 55 seconds for dwell index 
1500mm, 55 seconds for dwell index 1495mm, 45 seconds for dwell index 1490mm, and 45 
seconds for dwell index 1485mm for both ovoids.  This dwell-time combination results in a 
maximum dwell-time weighting difference for this set is thus 5%.   
Comparison of MC-simulated isodose distributions and isodoses calculated using TG-43 
methodology is shown in Figure 3.20.  The CT-MR compatible Fletcher ovoid illustration is to 
convey the size and placement of the ovoid pair.  Although the plane bisects the source dwell-
positions, and the source is only at a single location at any given time, the source is not 
illustrated.  Observed in this figure are the qualitative differences in dose due to the perturbing 
effects of the ovoids accounted for in MC simulations (dashed red lines) and unaccounted for in 
TG-43 calculations (solid blue line) for a single 2D plane.  Quantitatively, 26.6% of the 
comparison points are within +/- 2% or +/- 2mm.   
Comparisons of MC-simulated isodose distributions and isodoses calculated using TG-43 
methodology that has been corrected using an ovoid-based correction factor is shown in Figure 
3.21a.  Observed in this figure are the qualitative differences in dose for MC simulations (dashed 
red lines) and ovoid-based corrected TG-43 plan (solid blue line) for a single 2D plane. 
Quantitatively, 99.2% of the comparison points are within +/- 2% or +/- 2mm.  There are no 
appreciable differences between the MC simulation and ovoid-based corrected TG-43 plan. 
Next, comparisons for MC-simulated isodose distributions and isodoses calculated using 
TG-43 methodology that has been corrected using a source-based correction factor is shown in 
Figures 3.21b.  This figure illustrates the qualitative differences in dose for MC simulations 
(dashed red lines) and source-based corrected TG-43 plan (solid blue line) for a single 2D plane. 
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Quantitatively, 100% of the comparison points are within +/- 2% or +/- 2mm.  Again, there are 
no appreciable differences between the MC simulation and source-based corrected TG-43 plan. 
 
Figure 3.20:  Comparison of MC simulation of a mHDR v2 Ir-192 source contained in 
a modified CT-MR compatible Fletcher ovoid applicator to include a high-Z shield 
(red) vs. TG-43 calculations for a source in water (blue).  Maximum adjacent dwell-
time gradient is 5%.  Both ovoids are illustrated to show the plane and size of the 
ovoids.  Shown here are absolute dose comparisons, in Gy, for 8 dwell-positions (four 
per ovoid, dwell-position indices of 1500, 1495, 1490, 1485 mm for each ovoid).  
Quantitatively, 26.6% of the comparison points are within +/- 2% or +/- 2mm.   
61 
 
           (a)          (b) 
Figure 3.21:  Comparison of MC simulation of a mHDR v2 Ir-192 source contained in a modified CT-MR compatible Fletcher 
ovoid applicator to include high-Z shield vs. TG-43 corrected plans of a source in water.  Maximum adjacent dwell-time gradient 
is 5%.  Shown here are 2D planes bisecting the ovoid pair comparing full MC calculations (red) and isodoses calculated using (a) 
ovoid-based and (b) source-based corrected TG-43 plan (blue), in Gy, for 8 dwell-positions (four per ovoid, dwell-position indices: 
1500, 1495, 1490, 1485 mm for each ovoid).  Quantitatively, 99.2% and 100% of the comparison points are within +/- 2% or      
+/- 2mm for the ovoid-based and source-based corrected TG-43 plan, respectively.   
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3.3.1.2 Dwell-Time Gradient of 10% 
The dwell-times were manually set to 60 seconds for dwell index 1500mm, 60 seconds 
for dwell index 1495mm, 40 seconds for dwell index 1490mm, and 40 seconds for dwell index 
1485mm for both ovoids.  The maximum dwell-time gradient for this combination is 10%.   
Comparison of MC-simulated isodose distributions and isodoses calculated using TG-43 
methodology is shown in Figure 3.22.  The CT-MR compatible Fletcher ovoid illustration is to 
convey the size and placement of the ovoid pair.  Although the plane bisects the source dwell-
positions, and the source is only at a single location at any given time, the source is not 
illustrated.  Observed in this figure are the qualitative differences in dose due to the perturbing 
effects of the ovoids accounted for in MC simulations (dashed red lines) and unaccounted for in 
TG-43 calculations (solid blue line) for a single 2D plane.  Quantitatively, 30.1% of the 
comparison points are within +/- 2% or +/- 2mm.    
Comparisons of MC-simulated isodose distributions and isodoses calculated using TG-43 
methodology that has been corrected using an ovoid-based correction factor is shown in Figure 
3.23a.  Observed in this figure are the qualitative differences in dose for MC simulations (dashed 
red lines) and ovoid-based corrected TG-43 plan (solid blue line) for a single 2D plane. 
Quantitatively, 96.3% of the comparison points are within +/- 2% or +/- 2mm.    
Next, comparisons for MC-simulated isodose distributions and isodoses calculated using 
TG-43 methodology that has been corrected using a source-based correction factor is shown in 
Figures 3.23b.  This figure illustrates the qualitative differences in dose for MC simulations 
(dashed red lines) and source-based corrected TG-43 plan (solid blue line) for a single 2D plane. 
Quantitatively, 100% of the comparison points are within +/- 2% or +/- 2mm.  There are no 
appreciable differences between the MC simulation and source-based corrected TG-43 plan. 
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Figure 3.22: Comparison of  MC simulation of a mHDR v2 Ir-192 source contained in 
a modified CT-MR compatible Fletcher ovoid applicator to include a high-Z shield 
(red) vs. TG-43 calculations for a source in water (blue).  Maximum adjacent dwell-
time gradient is 10%.  Both ovoids are illustrated to show the plane and size of the 
ovoids.  Shown here are absolute dose comparisons, in Gy, for 8 dwell-positions (four 
per ovoid, dwell-position indices of 1500, 1495, 1490, 1485 mm for each ovoid).  
Quantitatively, 30.1% of the comparison points are within +/- 2% or +/- 2mm.   
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           (a)          (b) 
Figure 3.23(a-b):  Comparison of  MC simulation of a mHDR v2 Ir-192 source contained in a modified CT-MR compatible 
Fletcher ovoid applicator to include high-Z shield vs. TG-43 corrected plans of a source in water.  Maximum adjacent dwell-time 
gradient is 10%.  Shown here are 2D planes bisecting the ovoid pair comparing full MC calculations (red) and isodoses calculated 
using (a) ovoid-based and (b) source-based corrected TG-43 plan (blue), in Gy, for 8 dwell-positions (four per ovoid, dwell-
position indices: 1500, 1495, 1490, 1485 mm for each ovoid).  Quantitatively, 96.3% and 100% of the comparison points are 
within +/- 2% or +/- 2mm for the ovoid-based and source-based corrected TG-43 plan, respectively.   
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3.3.1.2 Dwell-Time Gradient of 15% 
The dwell-times, keeping the same plan, were manually set to 5 seconds for dwell index 
1500mm, 7.5 seconds for dwell index 1495mm, 45 seconds for dwell index 1490mm, and 67.5 
seconds for dwell index 1485mm for both ovoids.  The maximum dwell-time gradient for this 
combination is 30%.   
Comparison of MC-simulated isodose distributions and isodoses calculated using TG-43 
methodology is shown in Figure 3.24.  The CT-MR compatible Fletcher ovoid illustration is to 
convey the size and placement of the ovoid pair.  Although the plane bisects the source dwell-
positions, and the source is only at a single location at any given time, the source is not 
illustrated.  Observed in this figure are the qualitative differences in dose due to the perturbing 
effects of the ovoids accounted for in MC simulations (dashed red lines) and unaccounted for in 
TG-43 calculations (solid blue line) for a single 2D plane.  Quantitatively, 34.4% of the 
comparison points are within +/- 2% or +/- 2mm.    
Comparisons of MC-simulated isodose distributions and isodoses calculated using TG-43 
methodology that has been corrected using an ovoid-based correction factor is shown in Figure 
3.25a.  Observed in this figure are the qualitative differences in dose for MC simulations (dashed 
red lines) and ovoid-based corrected TG-43 plan (solid blue line) for a single 2D plane. 
Quantitatively, 85.9% of the comparison points are within +/- 2% or +/- 2mm.    
Next, comparisons for MC-simulated isodose distributions and isodoses calculated using 
TG-43 methodology that has been corrected using a source-based correction factor is shown in 
Figures 3.25b.  This figure illustrates the qualitative differences in dose for MC simulations 
(dashed red lines) and source-based corrected TG-43 plan (solid blue line) for a single 2D plane. 
Quantitatively, 100% of the comparison points are within +/- 2% or +/- 2mm.  There are no 
appreciable differences between the MC simulation and source-based corrected TG-43 plan. 
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Figure 3.24: Comparison of  MC simulation of a mHDR v2 Ir-192 source contained in 
a modified CT-MR compatible Fletcher ovoid applicator to include a high-Z shield 
(red) vs. TG-43 calculations for a source in water (blue).  Maximum adjacent dwell-
time gradient is 15%.  Both ovoids are illustrated to show the plane and size of the 
ovoids.  Shown here are absolute dose comparisons, in Gy, for 8 dwell-positions (four 
per ovoid, dwell-position indices of 1500, 1495, 1490, 1485 mm for each ovoid).  
Quantitatively, 34.4% of the comparison points are within +/- 2% or +/- 2mm.   
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           (a)          (b) 
Figure 3.25:  Comparison of MC simulation of a mHDR v2 Ir-192 source contained in a CT modified CT-MR compatible Fletcher 
ovoid applicator to include high-Z shield vs. TG-43 corrected plans of a source in water.  Maximum adjacent dwell-time gradient 
is 15%.  Shown here are 2D planes bisecting the ovoid pair comparing full MC calculations (red) and isodoses calculated using  
(a) ovoid-based and (b) source-based corrected TG-43 plan (blue), in Gy, for 8 dwell-positions (four per ovoid, dwell-position 
indices: 1500, 1495, 1490, 1485 mm for each ovoid).  Quantitatively, 85.9% and 100% of the comparison points are within +/- 2% 
or +/- 2mm for the ovoid-based and source-based corrected TG-43 plan, respectively.   
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3.3.1.2 Dwell-Time Gradient of 30% 
The dwell-times, keeping the same plan, were manually set to 5 seconds for dwell index 
1500mm, 7.5 seconds for dwell index 1495mm, 45 seconds for dwell index 1490mm, and 67.5 
seconds for dwell index 1485mm for both ovoids.  The maximum dwell-time weighting 
difference for this combination is 30%.   
Comparison of MC-simulated isodose distributions and isodoses calculated using TG-43 
methodology is shown in Figure 3.26.  The CT-MR compatible Fletcher ovoid illustration is to 
convey the size and placement of the ovoid pair.  Although the plane bisects the source dwell-
positions, and the source is only at a single location at any given time, the source is not 
illustrated.  Observed in this figure are the qualitative differences in dose due to the perturbing 
effects of the ovoids accounted for in MC simulations (dashed red lines) and unaccounted for in 
TG-43 calculations (solid blue line) for a single 2D plane.  Quantitatively, 66.9% of the 
comparison points are within +/- 2% or +/- 2mm.    
Comparisons of MC-simulated isodose distributions and isodoses calculated using TG-43 
methodology that has been corrected using an ovoid-based correction factor is shown in Figure 
3.27a.  Observed in this figure are the qualitative differences in dose for MC simulations (dashed 
red lines) and ovoid-based corrected TG-43 plan (solid blue line) for a single 2D plane. 
Quantitatively, 34.2% of the comparison points are within +/- 2% or +/- 2mm.    
Next, comparisons for MC-simulated isodose distributions and isodoses calculated using 
TG-43 methodology that has been corrected using a source-based correction factor is shown in 
Figures 3.27b.  This figure illustrates the qualitative differences in dose for MC simulations 
(dashed red lines) and source-based corrected TG-43 plan (solid blue line) for a single 2D plane. 
Quantitatively, 100% of the comparison points are within +/- 2% or +/- 2mm.  There are no 
appreciable differences between the MC simulation and source-based corrected TG-43 plan. 
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Figure 3.26: Comparison of  MC simulation of a mHDR v2 Ir-192 source contained in a 
modified CT-MR compatible Fletcher ovoid applicator to include a high-Z shield (red) 
vs. TG-43 calculations for a source in water (blue).  Maximum adjacent dwell-time 
gradient is 30%.  Both ovoids are illustrated to show the plane and size of the ovoids.  
Shown here are absolute dose comparisons, in Gy, for 8 dwell-positions (four per ovoid, 
dwell-position indices of 1500, 1495, 1490, 1485 mm for each ovoid).  Quantitatively, 
66.9% of the comparison points are within +/- 2% or +/- 2mm.   
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Figure 3.27:  Comparison of MC simulation of a mHDR v2 Ir-192 source contained in a modified CT-MR compatible Fletcher 
ovoid applicator to include high-Z shield vs. TG-43 corrected plans of a source in water.  Maximum adjacent dwell-time gradient 
is 30%.  Shown here are 2D planes bisecting the ovoid pair comparing full MC calculations (red) and isodoses calculated using 
(a) ovoid-based and (b) source-based corrected TG-43 plan (blue), in Gy, for 8 dwell-positions (four per ovoid, dwell-position 
indices: 1500, 1495, 1490, 1485 mm for each ovoid).  Quantitatively, 34.2% and 100% of the comparison points are within       
+/- 2% or +/- 2mm for the ovoid-based and source-based corrected TG-43 plan, respectively.   
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3.3.1.3 Dwell-time Gradient of 60% 
The dwell-times, keeping the same plan, were changed to 5 seconds for dwell index 
1500mm, 5 seconds for dwell index 1495mm, 35 seconds for dwell index 1490mm, and 155 
seconds for dwell index 1485mm for the left ovoid.  The right ovoid dwell-times are the same as 
the left, but the order of the dwell indices is flipped.  The maximum dwell-time gradient for this 
combination is 60%. 
Comparison of MC-simulated isodose distributions and isodoses calculated using TG-43 
methodology is shown in Figure 3.28.  The CT-MR compatible Fletcher ovoid illustration is to 
convey the size and placement of the ovoid pair.  Although the plane bisects the source dwell-
positions, and the source is only at a single location at any given time, the source is not 
illustrated.  Observed in this figure are the qualitative differences in dose due to the perturbing 
effects of the ovoids accounted for in MC simulations (dashed red lines) and unaccounted for in 
TG-43 calculations (solid blue line) for a single 2D plane.  Quantitatively, 10.5% of the 
comparison points are within +/- 2% or +/- 2mm.  . 
Comparisons of MC-simulated isodose distributions and isodoses calculated using TG-43 
methodology that has been corrected using an ovoid-based correction factor is shown in Figure 
3.29a.  Observed in this figure are the qualitative differences in dose for MC simulations (dashed 
red lines) and ovoid-based corrected TG-43 plan (solid blue line) for a single 2D plane. 
Quantitatively, 56.8% of the comparison points are within +/- 2% or +/- 2mm.   
Next, comparisons for MC-simulated isodose distributions and isodoses calculated using 
TG-43 methodology that has been corrected using a source-based correction factor is shown in 
Figures 3.29b.  This figure illustrates the qualitative differences in dose for MC simulations 
(dashed red lines) and source-based corrected TG-43 plan (solid blue line) for a single 2D plane. 
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Quantitatively, 100% of the comparison points are within +/- 2% or +/- 2mm.  There are no 
appreciable differences between the MC simulation and source-based corrected TG-43 plan. 
 
Figure 3.28:  Comparison of  MC simulation of a mHDR v2 Ir-192 source contained in 
a modified CT-MR compatible Fletcher ovoid applicator to include a high-Z shield 
(red) vs. TG-43 calculations for a source in water (blue).  Maximum adjacent dwell-
time gradient is 60%.  Both ovoids are illustrated to show the plane and size of the 
ovoids.  Shown here are absolute dose comparisons, in Gy, for 8 dwell-positions (four 
per ovoid, dwell-position indices of 1500, 1495, 1490, 1485 mm for each ovoid).  
Quantitatively, 10.5% of the comparison points are within +/- 2% or +/- 2mm.   
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           (a)          (b) 
Figure 3.29(a-b):  Comparison of MC simulation of a mHDR v2 Ir-192 source contained in a modified CT-MR compatible 
Fletcher ovoid applicator to include high-Z shield vs. TG-43 corrected plans of a source in water.  Maximum adjacent dwell-time 
gradient is 60%.  Shown here are 2D planes bisecting the ovoid pair comparing full MC calculations (red) and isodoses calculated 
using (a) ovoid-based and (b) source-based corrected TG-43 plan (blue), in Gy, for 8 dwell-positions (four per ovoid, dwell-
position indices: 1500, 1495, 1490, 1485 mm for each ovoid).  Quantitatively, 56.8% and 100% of the comparison points are 
within +/- 2% or +/- 2mm for the ovoid-based and source-based corrected TG-43 plan, respectively.   
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3.3.3 Summary of Results 
Table 3.1 lists the agreement (percent dose and DTA) for comparisons of MC simulated 
and TG-43 calculated 3D dose distributions utilizing a comparison dose cut-off of 50 cGy 
isodose line.   These results indicate that a TG-43 isodose calculation of a mHDR v2 Ir-192 
source in water agrees within the uncertainty of the MC simulation for any combination of 
dwell-time gradients.  Although ovoid- and source- based corrected plans had better agreement 
than TG-43 calculations with full MC datasets, the TG-43 calculations agree within the MC 
uncertainty.  For every dwell-time combination, the source- based corrected plan agreed 100% 
with the full MC dataset.   
Table 3.1:  Agreement of MC simulation with TG-43 data set, Ovoid-correction plan, and 
Source-correction plan.  Agreement metric:  2% or 2mm. 
∇ MC versus: 
Agreement 
(2%/2mm) 
0% 
TG-43 99.8% 
Ovoid-Correction plan 100% 
Source-Correction plan 100% 
30% 
TG-43 99.7% 
Ovoid-Correction plan 99.9% 
Source-Correction plan 100% 
60% 
TG-43 99.0% 
Ovoid-Correction plan 99.7% 
Source-Correction plan 100% 
70% 
TG-43 99.6% 
Ovoid-Correction plan 99.9% 
Source-Correction plan 100% 
 
Table 3.2 lists the agreement for comparisons between the simulations from the modified 
MC model which includes high-Z inhomogeneities.  This high-Z shield alteration to the CT-MR 
compatible Fletcher ovoid model was to test the robustness of the correction schemes for dose 
distributions that were relatively different to TG-43 dose calculations of a single source in water.  
This modification was studied since the MC simulations of a single source within the CT-MR 
compatible Fletcher ovoid agreed within the MC uncertainty with the TG-43 calculations of a 
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source in water.  As expected, there was not a single MC simulation that agreed within criteria 
when compared to the full MC dataset.  There is relatively higher agreement with the plan 
having a ∇dt equal to 30.  This can be a contributed to the dwell-time combination being utilized 
for this comparison.  This plan has the highest dwell-times at the dwell-positions farther from the 
shields and relatively low dwell-times near the shields.  The source- based corrected plans agreed 
100% with the full MC simulations.  Agreement was not affected on the difference between the 
TG-43 calculations compared to MC.  It seems as if the limiting factor for agreement was due to 
the maximum ∇dt.  Once the maximum ∇dt was above 10%, the ovoid- based correction scheme 
began to fail.   
Table 3.2:  Agreement of modified MC model simulation with TG-43 data set, Ovoid-correction 
plan, and Source-correction plan.  Agreement metric:  2% or 2mm. 
∇ MC versus: 
Agreement 
(2%/2mm) 
0% 
TG-43 13.2% 
Ovoid-Correction plan 100% 
Source-Correction plan 100% 
5% 
TG-43 26.6% 
Ovoid-Correction plan 99.2% 
Source-Correction plan 100% 
10% 
TG-43 30.1% 
Ovoid-Correction plan 96.3% 
Source-Correction plan 100% 
15% 
TG-43 34.4% 
Ovoid-Correction plan 85.9% 
Source-Correction plan 100% 
30% 
TG-43 67.0% 
Ovoid-Correction plan 59.1% 
Source-Correction plan 100% 
60% 
TG-43 10.5% 
Ovoid-Correction plan 56.8% 
Source-Correction plan 100% 
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3.4 Discussions 
Dose perturbations resulting from the ICBT CT-MR compatible Fletcher applicator set 
were relatively small and agreed to TG-43 calculations for a source in water within the 
uncertainty of the MC simulations (>99% points within +/-2% dose or 2mm DTA).  This is due 
to the main ovoid heterogeneity being polyphenylsulfone with a density very similar to water.  
This makes the entire MC model fairly homogeneous.  Thus, a correction scheme is not 
necessary. 
 The “shielded” ovoid applicator set did not agree to TG-43 calculations for a source in 
water.  This MC model was introduced to test the robustness of both correction schemes (ovoid- 
or source-based).  Dose perturbations were due to a significant ovoid heterogeneity.  The 
tungsten shield in this study is relatively larger than clinically-available ovoid shields.  
Correction factors were applied to TPS exported plans by developing software written in Matlab.  
Once the DICOM compatible files were compiled into a Matlab format, the software extracted 
treatment parameters such as dwell-times, dwell-coordinates, source activity, dose grid size, and 
dose grid axis indexes.  These parameters were then applied to the MC simulation to generate an 
equivalent treatment plan. 
Plans generated by Oncentra TPS with a maximum dwell-time gradient less than 10% 
can be corrected utilizing either the ovoid-based or source-based correction methods to agree 
with full simulated Monte Carlo datasets to within +/- 2% or +/- 2mm DTA.  Although, dwell-
time combinations utilized in this study with a maximum dwell-time gradient above 10% is a 
threshold for the ovoid- based correction scheme to correct the TG-43 calculation.  The source- 
based correction method consistently results in 100% agreement between a corrected plan and 
the equivalent MC generated plan.   
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For brachytherapy plans with equivalent dwell-times, as typically found with plans 
generated using the Manchester system, either correction scheme is appropriate.  Treatment plans 
that generate a “patient” specific dose distribution, rather than the dose distribution inherent to 
the tandem and ovoid applicator (i.e. pear shape), to cover the disease need to utilize the source- 
based correction method.  A “patient” specific dose distribution is commonly generated utilizing 
the GEC ESTRO dose specification. 
It should be noted that this correction scheme requires a CT dataset that does not contain 
high-Z artifacts.  This criterion is made possible only with Nucletron’s Anatomically Adaptive 
Applicator.  Currently, investigations are being made that by using a MVCT (as opposed to a 
kVCT) scan, high-Z artifacts can be reduced significantly.   
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Chapter 4 Conclusions 
4.1 Summary of Results 
 This study was able to confirm the absolute dose distributions calculated by MCNPX for 
a CT-MR compatible ICBT applicator.  We demonstrated that our MC modeling of a paired 
ovoid set (without surrogate shield) is accurate and robust enough to simulate dose distributions 
with sufficient accuracy within the context of this study.   
 Ovoid- and source-based correction factors were created for a clinically utilized ovoid 
paired set (with and without shield surrogate) for four dwell positions per ovoid with a 5mm 
step-size.  In all, there were two ovoid- based correction factors for each ovoid (left and right) 
and eight source- based correction factors for each individual dwell positions.   
 Plans calculated utilizing Oncentra were corrected to include dose perturbations from the 
“shielded” ovoid set.  The ovoid- based correction factors improved TG-43 calculated plans with 
maximum dwell-time gradients of less than 10%.  The source- based correction scheme 
consistently generated results that agreed 100% with the full MC simulation.   
4.2 Evaluation of Hypothesis 
“A 3D Monte Carlo-simulated dose distribution of the ovoid contribution to a cervical 
intracavitary brachytherapy (ICBT) treatment administered via Nucletron’s Fletcher CT-MR 
ovoid applicator (Nucletron Corporation, Veenendaal, The Netherlands), modeled with and 
without a rectal shield surrogate, will agree, within criteria, with the dose distribution resulting 
from an equivalent treatment calculated using AAPM Task Group-43 (TG-43) methodology 
when corrected for heterogeneities using pre-calculated MC correction factors applied (a) to 
individual source dwell-positions and (b) individual ovoids acting as multi-source surrogates for 
varying adjacent dwell-time gradients (∇dt).  Criteria are defined as agreement within +/- 2% or 
+/- 2 mm distance-to-agreement.” 
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The results of this research support part of the hypothesis that applicator correction 
factors calculated for individual source, as opposed to ovoid, positions are required to predict 
intracavitary brachytherapy dose distributions that agree with Monte Carlo simulations to within 
2% dose or 2mm DTA for dwell-time gradients greater than 10%.  However, for dwell-time 
gradients below 10%, either correction scheme (ovoid- or source- based) will result in a dose 
distribution that agrees within criteria.   
4.3 Future Work 
 Since dose grids larger than 7x7x7cm (1mm
3 
resolution) are too large to process using the 
Gridconv auxiliary MCNPX program [11], another method should be sought out to convert the 
MC output to a format that can be integrated into the process utilized in this study.  A larger MC 
dose grid on the order of 16cm
3
 should be processed in order to account for translation of the 
sources in a 10x10x10cm
3
 dose grid.  This will allow for the corrected dose distribution to be 
added to the tandem contribution of the ICBT procedure without losing dose information beyond 
the distal end of the tandem. 
The method presented in this study utilizing MATLAB does not allow for a multi-frame 
DICOM file to be generated.  Another strategy should be sought out so that the corrected dose 
distribution can be imported to Oncentra in DICOM format for plan analysis. 
Nucletron’s next generation TPS utilizes Collapsed Cone Convolution to calculate 
patient-specific dose distributions.  Although the CCC algorithm cannot handle large 
perturbations in dose due to high-Z heterogeneities like those introduced by intra-ovoid 
shielding.  The methods presented in this work can be used to correct these dose distributions for 
the effect of ovoid shielding, thus providing an accurate representation of dose delivered to a 
patient undergoing ICBT. 
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Appendix 1 Process Digitized Film (.tiff images) and Calculate 
Standard Deviation 
% This processes .tiff images and calculates the average standard deviation 
% and the standard deviation of the standard deviation... 
% Input: 3 processed (scanned) RCF datasets as .tiff images 
%Import films 
D1 = double(imread('disease1001.tif')); 
D2 = double(imread('disease2001.tif')); 
D3 = double(imread('disease3001.tif')); 
%Red channel 
gFilmOne1=D1(:,:,1); 
gFilmOne2=D2(:,:,1); 
gFilmOne3=D3(:,:,1); 
%Smooth 
gFilmOne1=wiener2(gFilmOne1); 
gFilmOne2=wiener2(gFilmOne2); 
gFilmOne3=wiener2(gFilmOne3); 
%Crop.. index specified by location on flat-bed scanner 
gFilmOne1crop=gFilmOne1(150:580,150:580); 
gFilmOne2crop=gFilmOne2(150:580,150:580); 
gFilmOne3crop=gFilmOne3(150:580,150:580); 
%Resolution 
info = imfinfo('disease1001.tif'); 
xresolution = info.XResolution; 
yresolution = info.YResolution; 
xres_setting = (2.54)/xresolution; 
yres_setting = (2.54)/yresolution; 
%Interpolate to 1mm^3 
[rowsfilm colsfilm] = size(gFilmOne1crop); 
xx = 0 : xres_setting : xres_setting * (rowsfilm - 1); 
yy = 0 : yres_setting : yres_setting * (colsfilm - 1); 
xend = floor(xres_setting * (rowsfilm - 1)); 
yend = floor(yres_setting * (colsfilm - 1)); 
XI = 0:0.1:xend; 
YI = 0:0.1:yend; 
%Film 1 
for i = 1:(11*10+1); 
for j = 1:(11*10+1); 
iFilmOne(j,i) = interp2(yy,xx,gFilmOne1crop,XI(i),YI(j),'*linear'); 
end 
end; 
%Crop to 101 x 101 dose grid to match MC 
gFilmOne1_interp = iFilmOne(1:101,11:111); 
%Convert scanner values to absolute dose (calibration curve) 
gF1 = arrayfun(@(x) 0.000000021448218*x.^2 - 0.002274568204140*x +... 
    61.167641732761900, gFilmOne1_interp); 
%Film 2 
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for i = 1:(11*10+1); 
for j = 1:(11*10+1); 
iFilmOne(j,i) = interp2(yy,xx,gFilmOne2crop,XI(i),YI(j),'*linear'); 
end 
end; 
%Crop to 101 x 101 dose grid to match MC 
gFilmOne2_interp = iFilmOne(1:101,11:111); 
%Convert scanner values to absolute dose (calibration curve) 
gF2 = arrayfun(@(x) 0.000000021448218*x.^2 - 0.002274568204140*x +... 
    61.167641732761900, gFilmOne2_interp); 
%Film 3 
for i = 1:(11*10+1); 
for j = 1:(11*10+1); 
iFilmOne(j,i) = interp2(yy,xx,gFilmOne3crop,XI(i),YI(j),'*linear'); 
end 
end; 
%Crop to 101 x 101 dose grid to match MC 
gFilmOne3_interp = iFilmOne(1:101,11:111); 
%Convert scanner values to absolute dose (calibration curve) 
gF3 = arrayfun(@(x) 0.000000021448218*x.^2 - 0.002274568204140*x +... 
    61.167641732761900, gFilmOne3_interp); 
%average data sets 
mean=(gF1+gF2+gF3)/3; 
%Number of .tiff images 
N=3; 
sigma_map=zeros(101,101); 
count=0; 
%calculate sigma 
for i = 1:101, 
    for j = 1:101, 
        x_mean=mean(i,j); 
        x_i_1 = gF1(i,j); 
        x_i_2 = gF2(i,j); 
        x_i_3 = gF3(i,j); 
        l = (x_i_1 - x_mean)^2; 
        m = (x_i_2 - x_mean)^2; 
        n = (x_i_3 - x_mean)^2; 
numerator = l+m+n; 
         sigma_map(i,j)= sqrt(numerator/(N-1)); 
        count = count+sigma_map(i,j); 
    end 
end 
 sigma_map_mean = (sigma_map/sqrt(N)); 
 %standard deviation of the average standard deviation 
average_of_sigmas = count/(101*101); 
summation=0; 
for i = 1:101, 
    for j = 1:101, 
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        x_i=sigma_map_mean(i,j); 
        x_mean = average_of_sigmas; 
      
        difference=(x_i - x_mean)^2; 
         
        summation = summation+difference; 
     end 
end 
standard_deviation_of_sigma = sqrt(summation/(101*101)); 
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Appendix 2 Compile Dose Grid from a RD DICOM File 
%Input:RD_DICOM (.dcm extension) from TPS 
%DICOM scales the dose grid down, obtain scaling factor using dicominfo to 
%scale back into actual values 
factor = dicominfo('filename.dcm'); 
dosegridscaling = double(factor.DoseGridScaling); 
%Dose grid dimensions 
frames = factor.NumberOfFrames; 
rows = factor.Rows; 
columns = factor.Columns; 
%Create a matrix the same size as DICOM dose grid 
Empty = double(zeros(frames,rows,columns)); 
%Compile all 2D frames to develop 3D dose grid 
for i = 1:frames, 
      b = double(dicomread('filename.dcm','frames',i)); 
      Empty(:,i,:) = b(101:-1:1,:,:) * dosegridscaling; 
end; 
%Name Dose grid, and save it as .mat file 
RENAME = Empty; 
save('RENAME','RENAME'); 
%end 
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Appendix 3 Dose Tolerance and Distance to Agreement Algorithm 
% Calculates the percentage of points that agree within percent tolerance 
% of absolute dose or able to locate a valid point within specified distance. 
% Input: 2 matrices the same size (measured, calculated) 
% Resolution must be 1mm^3 
% DTA specified in mm, Dose tolerance specified in percent (i.e. 2 %) 
% Low limit threshold specified in same unit as dose grid values 
measured = compare1; 
calculated = compare2; 
DTA = 3; 
tolerance = 3; 
limit = 3; 
% Pass/fail matrix, same size as input 
% Begins with all 10s, when a point passes, replaces it with value of 1. 
% (i.e. points above 1 fail) 
size1 = size(measured); 
passfail = zeros(size1(1),size1(2),size1(3)); 
passfail = passfail + 10; 
% tallies = 0 to begin 
passtally = 0; 
falsetally = 0; 
totaltally = 0; 
highlimit = 0; 
lowlimit = 0; 
blackbox = 0; 
%Begin DTA algorithm 
for i = 1:size1(1); 
    for j = 1:size1(2); 
        for k = 1:size1(3); 
% Condition statements to kickout points below limit threshold, 
% above high limit threshold, or within a blackbox (for this study, 
% non-relative clinical points were set to negative values) 
            if calculated(i,j,k) <= limit && calculated(i,j,k) >= 0, 
               lowlimit = lowlimit + 1; 
            else 
            if measured(i,j,k) <= limit && measured(i,j,k) >= 0, 
               lowlimit = lowlimit + 1; 
            else 
            if calculated(i,j,k) > 15 || measured(i,j,k) > 15 , 
               highlimit = highlimit + 1; 
            else 
            if calculated(i,j,k) <= 0 || measured(i,j,k) <= 0, 
               blackbox = blackbox + 1; 
            else 
% If point does not fall within condition statements above, it is used as a 
% valid comparison point for agreement analysis. 
            totaltally = totaltally + 1; 
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% Check if corresponding pixel is within tolerance.  If sufficient, no more 
% comparisons are needed and the process starts over, otherwise.. continue 
            if abs((((calculated (i, j, k) - measured(i, j, k)))/(measured(i, j, k))*100)) <= tolerance, 
               passfail(i,j,k) = 1; 
               passtally = passtally + 1; 
            else 
%Begin "Neighborhood" search for value within tolerance 
% Define indexes that construct neighborhood 
            startrow = i - DTA; 
            endrow = i + DTA; 
            startcol = j - DTA; 
            endcol = j + DTA; 
            startheight = k - DTA; 
            endheight = k + DTA; 
% Boundary fix 
            if startrow <= 0, startrow = i; end 
            if endrow > size1(1), endrow = size1(1); end 
            if startcol <= 0, startcol = j; end 
            if endcol > size1(2), endcol = size1(2); end 
            if startheight <= 0, startheight = k; end 
            if endheight > size1(3), endheight = size1(3); end 
%Neighborhood of pixels of measured with respect to calc(i, j, k). 
            neighborhood = measured(startrow:endrow,startcol:endcol,startheight:endheight); 
            numrows = endrow - startrow + 1; 
            numcols = endcol - startcol + 1; 
            numheight = endheight - startheight + 1; 
% Minigrid is small version of pass/fail conditions 
% Caution, kickout conditions are not evaluated for neighborhood search 
            minigrid = zeros(numrows,numcols,numheight); 
            Dosediff_criterion = zeros(numrows,numcols,numheight); 
% Search neighborhood for a point that passes both criterions 
            for r = 1:numrows; 
                for s = 1:numcols; 
                    for t = 1:numheight; 
                        calcpt = calculated(i,j,k); 
%Step pixels from end to start. 
                        rowstep = (r - (DTA + 1)); 
                        colstep = (s - (DTA + 1)); 
                        heightstep = (t - (DTA + 1)); 
                        newrow = i - rowstep; 
                        newcol = j - colstep; 
                        newheight = k - heightstep; 
%Check distance of neighborhood pixel. 
                        distance = sqrt(((i-newrow)^2 + (j-newcol)^2 + (k-newheight)^2)); 
%Check if corresponding pixel is within tolerance. 
                        Dosediff_criterion(r,s,t) = abs((((calcpt - neighborhood(r,s,t))... 
                            /(neighborhood(r,s,t)))*100)); 
                        if (distance <= DTA) && (Dosediff_criterion(r,s,t) <= tolerance), 
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                                        minigrid(r,s,t) = 1; 
                        else 
                        minigrid(r,s,t) = 5; 
                        end; 
                    end; 
                end; 
            end; 
%End "Neighborhood" search for value within tolerance 
            passfail(i, j, k) = min(min(min(minigrid))); 
%If passfail point passes, add 1 to passtally, if not 
%add one to falsetally 
            if passfail(i,j,k) <=  1, 
               passtally = passtally + 1; 
            else 
               falsetally = falsetally + 1; 
            end; 
        end; 
% End kickout 'if' conditional statements 
        end; 
        end; 
        end; 
        end; 
% End i,j,k loops 
        end; 
 end; 
end; 
passrate = floor((passtally/(passtally+falsetally))*100); 
%Send passrate to command window 
passrate 
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Appendix 4 Define Plan Parameters from RP, RD DICOM Files  
% for a Plan Consisting of Two Ovoids with 6 out of 8 Active Dwell-Positions 
%Dig for variables to build MC dose distribution 
infoRP = dicominfo('RPT.dcm'); 
infoRD = dicominfo('RDT.dcm'); 
 %Find right ovoid source coordinates 
coordinateRT1 = infoRP.ApplicationSetupSequence.Item_1.ChannelSequence.Item_5.Brachy... 
    ControlPointSequence.Item_2.ControlPoint3DPosition; 
coordinateRT2 = infoRP.ApplicationSetupSequence.Item_1.ChannelSequence.Item_5.Brachy... 
    ControlPointSequence.Item_4.ControlPoint3DPosition; 
coordinateRT3 = infoRP.ApplicationSetupSequence.Item_1.ChannelSequence.Item_5.Brachy... 
    ControlPointSequence.Item_6.ControlPoint3DPosition; 
%listed as x, y, z 
R1500 = [ (coordinateRT1(3)) (coordinateRT1(1)) -(coordinateRT1(2)) ]; 
R1495 = [ (coordinateRT2(3)) (coordinateRT2(1)) -(coordinateRT2(2)) ]; 
R1490 = [ (coordinateRT3(3)) (coordinateRT3(1)) -(coordinateRT3(2)) ]; 
%left 
coordinateLT1 = infoRP.ApplicationSetupSequence.Item_1.ChannelSequence.Item_4.Brachy... 
    ControlPointSequence.Item_2.ControlPoint3DPosition; 
coordinateLT2 = infoRP.ApplicationSetupSequence.Item_1.ChannelSequence.Item_4.Brachy... 
    ControlPointSequence.Item_4.ControlPoint3DPosition; 
coordinateLT3 = infoRP.ApplicationSetupSequence.Item_1.ChannelSequence.Item_4.Brachy... 
    ControlPointSequence.Item_6.ControlPoint3DPosition; 
L1500 = [ (coordinateLT1(3)) (coordinateLT1(1)) -(coordinateLT1(2)) ]; 
L1495 = [ (coordinateLT2(3)) (coordinateLT2(1)) -(coordinateLT2(2)) ]; 
L1490 = [ (coordinateLT3(3)) (coordinateLT3(1)) -(coordinateLT3(2)) ]; 
%Decimal spot 
R1500x = sign(coordinateRT1(3))*(abs(coordinateRT1(3)) - abs(fix(coordinateRT1(3)))); 
R1500y = sign(coordinateRT1(1))*(abs(coordinateRT1(1)) - abs(fix(coordinateRT1(1)))); 
R1500z = -sign(coordinateRT1(2))*(abs(coordinateRT1(2)) - abs(fix(coordinateRT1(2)))); 
R1495x = sign(coordinateRT2(3))*(abs(coordinateRT2(3)) - abs(fix(coordinateRT2(3)))); 
R1495y = sign(coordinateRT2(1))*(abs(coordinateRT2(1)) - abs(fix(coordinateRT2(1)))); 
R1495z = -sign(coordinateRT2(2))*(abs(coordinateRT2(2)) - abs(fix(coordinateRT2(2)))); 
R1490x = sign(coordinateRT3(3))*(abs(coordinateRT3(3)) - abs(fix(coordinateRT3(3)))); 
R1490y = sign(coordinateRT3(1))*(abs(coordinateRT3(1)) - abs(fix(coordinateRT3(1)))); 
R1490z = -sign(coordinateRT3(2))*(abs(coordinateRT3(2)) - abs(fix(coordinateRT3(2)))); 
%left 
L1500x = sign(coordinateLT1(3))*(abs(coordinateLT1(3)) - abs(fix(coordinateLT1(3)))); 
L1500y = sign(coordinateLT1(1))*(abs(coordinateLT1(1)) - abs(fix(coordinateLT1(1)))); 
L1500z = sign(coordinateLT1(2))*(abs(coordinateLT1(2)) - abs(fix(coordinateLT1(2)))); 
L1495x = sign(coordinateLT2(3))*(abs(coordinateLT2(3)) - abs(fix(coordinateLT2(3)))); 
L1495y = sign(coordinateLT2(1))*(abs(coordinateLT2(1)) - abs(fix(coordinateLT2(1)))); 
L1495z = sign(coordinateLT2(2))*(abs(coordinateLT2(2)) - abs(fix(coordinateLT2(2)))); 
L1490x = sign(coordinateLT3(3))*(abs(coordinateLT3(3)) - abs(fix(coordinateLT3(3)))); 
L1490y = sign(coordinateLT3(1))*(abs(coordinateLT3(1)) - abs(fix(coordinateLT3(1)))); 
L1490z = sign(coordinateLT3(2))*(abs(coordinateLT3(2)) - abs(fix(coordinateLT3(2)))); 
%Adjust to tenths of a millimeter 
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R1500z = R1500z/10; 
R1495z = R1495z/10; 
R1490z = R1490z/10; 
L1500z = L1500z/10; 
L1495z = L1495z/10; 
L1490z = L1490z/10; 
R1500y = R1500y/10; 
R1495y = R1495y/10; 
R1490y = R1490y/10; 
L1500y = L1500y/10; 
L1495y = L1495y/10; 
L1490y = L1490y/10; 
R1500x = R1500x/10; 
R1495x = R1495x/10; 
R1490x = R1490x/10; 
L1500x = L1500x/10; 
L1495x = L1495x/10; 
L1490x = L1490x/10; 
 %source activity given as air kerma rate. 
activity = infoRP.SourceSequence.Item_1.ReferenceAirKermaRate; 
% Partial dwell-time weights..  
% Subtract--> BrachyControlPointSequence.Item_y (even# - odd#) 
part1500R = (infoRP.ApplicationSetupSequence.Item_1.ChannelSequence.Item_5.Brachy... 
    ControlPointSequence.Item_2.CumulativeTimeWeight)-(infoRP.ApplicationSetup... 
    Sequence.Item_1.ChannelSequence.Item_5.BrachyControlPointSequence.Item_1.Cumu... 
    lativeTimeWeight); 
part1495R = (infoRP.ApplicationSetupSequence.Item_1.ChannelSequence.Item_5.Brachy... 
    ControlPointSequence.Item_4.CumulativeTimeWeight)-(infoRP.ApplicationSetup... 
    Sequence.Item_1.ChannelSequence.Item_5.BrachyControlPointSequence.Item_3.Cumu... 
    lativeTimeWeight); 
part1490R = (infoRP.ApplicationSetupSequence.Item_1.ChannelSequence.Item_5.Brachy... 
    ControlPointSequence.Item_6.CumulativeTimeWeight)-(infoRP.ApplicationSetup... 
    Sequence.Item_1.ChannelSequence.Item_5.BrachyControlPointSequence.Item_5.Cumu... 
    lativeTimeWeight); 
%total time weight 
finalR = infoRP.ApplicationSetupSequence.Item_1.ChannelSequence.Item_5.FinalCumu... 
    lativeTimeWeight; 
%Total dwell-time 
channeltimeR = infoRP.ApplicationSetupSequence.Item_1.ChannelSequence.Item_5.Chan... 
    nelTotalTime; 
%Calculate dwell-time 
dwelltime1500R = double((part1500R)/(finalR)*(channeltimeR)); 
dwelltime1495R = double((part1495R)/(finalR)*(channeltimeR)); 
dwelltime1490R = double((part1490R)/(finalR)*(channeltimeR)); 
 %LOvoid,difference x--> infoRP.ApplicationSetupSequence.Item_1.ChannelSequence.Item_x  
part1500L = (infoRP.ApplicationSetupSequence.Item_1.ChannelSequence.Item_4.Brachy... 
    ControlPointSequence.Item_2.CumulativeTimeWeight)-(infoRP.ApplicationSetup... 
    Sequence.Item_1.ChannelSequence.Item_4.BrachyControlPointSequence.Item_1.Cumu... 
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    lativeTimeWeight); 
part1495L = (infoRP.ApplicationSetupSequence.Item_1.ChannelSequence.Item_4.Brachy... 
    ControlPointSequence.Item_4.CumulativeTimeWeight)-(infoRP.ApplicationSetup... 
    Sequence.Item_1.ChannelSequence.Item_4.BrachyControlPointSequence.Item_3.Cumu... 
    lativeTimeWeight); 
part1490L = (infoRP.ApplicationSetupSequence.Item_1.ChannelSequence.Item_4.Brachy... 
    ControlPointSequence.Item_6.CumulativeTimeWeight)-(infoRP.ApplicationSetup... 
    Sequence.Item_1.ChannelSequence.Item_4.BrachyControlPointSequence.Item_5.Cumu... 
    lativeTimeWeight); 
%total time weight 
finalL = infoRP.ApplicationSetupSequence.Item_1.ChannelSequence.Item_4.FinalCumu... 
    lativeTimeWeight; 
%Total dwell-time 
channeltimeL = infoRP.ApplicationSetupSequence.Item_1.ChannelSequence.Item_4.Chan... 
    nelTotalTime; 
%Calculate dwell-time 
dwelltime1500L = double((part1500L)/(finalL)*(channeltimeL)); 
dwelltime1495L = double((part1495L)/(finalL)*(channeltimeL)); 
dwelltime1490L = double((part1490L)/(finalL)*(channeltimeL)); 
%Calculate the MC conversion factor for each dwell-position 
%Rotation parameters searches RD DICOM  
%x,y,z unit vectors along primary axis 
x = [1;0;0]; 
y = [0;1;0]; 
z = [0;0;1]; 
 array = infoRD.GridFrameOffsetVector; 
checkarray = array'; 
dimension = (infoRD.ImagePositionPatient); 
DCMframes = infoRD.NumberOfFrames; 
DCMrows = infoRD.Rows; 
DCMcolumns = infoRD.Columns; 
 % Subtract coordinates to get a vector originating from first and ending at 
% the second.  Results in a vector originating from (0, 0, 0) to second 
% dwell coordinate (should be approximately 5mm in length) 
differenceR1 = R1490 - R1495; 
%Vector in the xy plane 
xycalc = [differenceR1(1); differenceR1(2); 0]; 
%Use geometry to solve for angles to orient seeds (This just solves for the 
%angle in the dot product of two vectors) 
zangleR = ((-acosd((dot(differenceR1,z))/(norm(z)*norm(differenceR1))))); 
xangleR = acosd((dot(xycalc,x))/(norm(x)*norm(xycalc))); 
yangleR = acosd((dot(xycalc,y))/(norm(y)*norm(xycalc)))-90; 
%Get unit vector pointing in the direction of the bottom dwells 
differenceL1 = L1490 - L1495; 
%Vector in the xy plane 
xycalc = [differenceL1(1); differenceL1(2); 0]; 
%Use geometry to solve for angles to orient seeds 
zangleL = ((-acosd((dot(differenceL1,z))/(norm(z)*norm(differenceL1))))); 
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xangleL = acosd((dot(xycalc,x))/(norm(x)*norm(xycalc))); 
yangleL = acosd((dot(xycalc,y))/(norm(y)*norm(xycalc)))-90; 
 %Parameters to expand small dose grids to larger so that a rotation can be 
%applied. 
%50 used because grid dimensions were 101x101x101 
MCexpand=201; 
shift = (MCexpand - 101)/2; 
DICOMxgrid = (dimension(1)+50); 
DICOMygrid = (dimension(3)+50); 
DICOMzgrid = -(dimension(2)+50); 
 DICOMsetxgrid = dimension(1); 
DICOMsetygrid = dimension(3); 
DICOMsetzgrid = dimension(2); 
%Dose grid indexes for MC dose grid 
xgridMC = (0:0.1:0.1*(MCexpand-1))-((MCexpand-1)/20); 
ygridMC = (0:0.1:0.1*(MCexpand-1))-((MCexpand-1)/20); 
zgridMC = (0:0.1:0.1*(MCexpand-1))-((MCexpand-1)/20); 
%Dose grid indexes compiled from DICOM file.. should match above 
xgrid = checkarray + dimension(1); 
xgrid = xgrid./10; 
ygrid = checkarray + dimension(3); 
ygrid = ygrid./10; 
zgrid = checkarray + dimension(2); 
zgrid = zgrid./10; 
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Appendix 5 Dose Grid 3D Rotation 
%filename (listed in interpolate function) is dose file to be rotated 
%Frames, rows, columns defined in DICOM 
m = frames; 
n = rows; 
q = columns; 
 
%Create a list of coordinates from indexes 
%e.g. xgridMC = 0:0.1:0.1*101 
[X1 Y1 Z1] = meshgrid(xgridMC, ygridMC, zgridMC); 
%Rotation matrix for each axis 
xaxis = [       1             0                  0         ;... 
                     0           cosd(xangleL)     -sind(xangleL)   ;... 
                     0           sind(xangleL)     cosd(xangleL)   ]; 
yaxis = [   cosd(yangleL)       0             sind(yangleL)    ;... 
                    0                         1                  0         ;... 
               -sind(yangleL)        0              cosd(yangleL)  ]; 
zaxis = [   cosd(zangleL1)     -sind(zangleL1)         0         ;... 
                sind(zangleL1)       cosd(zangleL1)          0         ;... 
                           0                           0                        1        ]; 
  
%Use matrix multiplication to rotate all at once 
rotation_matrix = yaxis*xaxis*zaxis; 
 
%Apply coordinate rotation 
XYZ_rotated = (C1)*[X1(:) Y1(:) Z1(:)].'; 
  
%Map rotation from old coordinates to new coordinates 
newXYZlist = interp3(X1,Y1,Z1,filename,XL1,YL1,ZL1); 
 
%reshape dose grid from blocklist format to a cube 
XYZmatrix = reshape(newXYZlist,[m n q]); 
XYZmatrix (isnan(XYZmatrix))=0; 
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